Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
03/2012 | Recent  |  14: Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions March listing by industry category 03/12

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
03/29/2012 > 159 patent applications in 120 patent subcategories. listing by industry category

20120077730 - method for in vitro molecular evolution of protein function: The invention provides a method for generating a polynucleotide sequence or population of sequences from parent polynucleotide sequences, the method comprising the steps of (a) providing a population of parent polynucleotide molecules, which population comprises plus and minus strands, (b) treating the population of parent polynucleotide molecules to generate a... Agent:

20120077731 - Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through... Agent: Ablynx N.v.

20120077732 - Cyclic peptides and uses thereof: The present invention relates to cyclic peptides, comprising alternating D- and L- amino acids and wherein the peptide possesses immunomodulatory activity. The present invention also relates to pharmaceutical compositions comprising the cyclic peptides and to methods for the treatment of disease.... Agent: Sydney West Area Health Service

20120077733 - Antagonists against interaction of pf4 and rantes: The invention relates to polypeptides of amino acid sequence SEQ ID NO: 1 according to formula (1), the use thereof for producing a medicament, and medicaments for the treatment of diseases related to monocyte recruitment.... Agent: Rwth Aacehn

20120077734 - Methods and assays for treating conditions in which macrophages play a pathogenic role: Methods and assays are disclosed for treating a subject with a disease or condition in which macrophages play a pathogenic role using agents that inhibit or down regulate Wiskott-Aldrich syndrome protein (WASP).... Agent:

20120077735 - Prophylactic agent for renal failure: The present invention provides an agent having a suppressive action against kidney glomerular disease and renal arteriosclerosis, a prophylactic agent for renal failure containing the above described agent, and functional foods expected to have a prophylactic effect for renal failure. The agent for preventing kidney glomerular disease and renal arteriosclerosis... Agent:

20120077736 - Inhibitor against forming biofilm comprising k-casein macropeptide: An inhibitor against the formation of biofilm includes κ-casein macropeptide. The inhibitor prevents or reduces the formation of a biofilm by inhibiting attachment or attachment/invasion followed by biofilm formation on the abiotic or biotic surfaces by L. monocytogenes. The inhibitor can be applied as a food or pharmaceutical additive, a... Agent: Industry Foundation Of Chonnam National University

20120077738 - Compositions and methods for predicting hcv susceptibility to antiviral agents: Methods for determining the susceptibility of a hepatitis C virus (HCV) in a patient to anti-viral agents, particularly cyclophilin inhibitors such as cyclosporine A, are disclosed. The methods include determining the amino acid sequence within a region of the HCV NS5A protein and comparing the viral amino acid sequence to... Agent: Wisconsin Alumni Research Foundation

20120077737 - Hepatitis c inhibitor compounds: Compounds of the invention, which are macrocyclic peptide analogs containing an acylsulfonamide moiety, maintain good activity against NS3 proteases containing clinically relevant resistance mutations for this class as represented by genotype 1a R155K, genotype 1b D168V and genotype 1a D168V resistance mutations. The compounds of the invention are useful as... Agent: Boehringer Ingelheim International Gmbh

20120077739 - Methods for treating obesity employing an sglt2 inhibitor and compositions thereof: Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which... Agent: Bristol-myers Squibb

20120077740 - Methods for making apo-2 ligand using divalent metal ions: Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed... Agent: Genentech, Inc.

20120077742 - Expression system of nell peptide: Recombinant NELL peptides and methods of preparing the same are disclosed.... Agent: The Regents Of The University Of California

20120077741 - Treatment of central nervous system disorders: The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central... Agent: Neuronova Ab

20120077743 - Methods of treating cartilage defects: The present invention provides methods of repairing and regenerating cartilage tissue by administering into the cartilage or the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein.... Agent:

20120077744 - Steroid-sparing methods of treating brain edema: The present invention relates to therapeutic regimens or protocols designed for the treatment, management or prevention of edema. In particular, the invention pertains to methods of treating or managing edema associated with brain tumors involving the administration of a therapeutically effective amount of corticorelin acetate that achieves a steroid-sparing effect.... Agent: Neutron Limited

20120077745 - Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues: The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of... Agent: Helsinn Therapeutics (u.s.), Inc.

20120077746 - Glp-1 analogues pharmaceutical compositions: The present invention is directed to sustained release liquid pharmaceutical compositions comprising a liquid, a peptide analogue according to the formula [Aib8,35]hGLP-1 (7-36)NH2, a divalent metal and/or divalent metal salt, and an acetate salt and/or acetic acid. The invention also relates to containers comprising the pharmaceutical compositions and methods for... Agent: Ipsen Pharma S.a.s.

20120077747 - Fish-derived protein lysate, and uses thereof as immunomodulatory and/or anti-inflammatory agent: A peptide-comprising extract derived from fish is described. Also disclosed is a process for obtaining a peptide-comprising extract derived from fish, as well as an extract obtained by this process. Compositions comprising such an extract are also described. Uses of such extracts/compositions, as well as corresponding methods of treatment, for... Agent: Innovactiv Inc.

20120077748 - Materials and methods for improving gastrointestinal function: The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa. In preferred embodiments, the composition comprises one or more nutrients and/or electrolytes that acquire or retain considerable absorptive capacity.... Agent:

20120077749 - Biologically active peptides: e

20120077750 - Use of a growth-stimulating protein: This invention relates to the inhibition of a newly discovered growth-stimulating protein in an individual. Further, the invention relates to a method for preventing or treating a cancer, or preventing or treating cancer growth, invasion or metastasis, or preventing or treating other hyperproliferative diseases in an individual, by down regulating... Agent:

20120077752 - Composition for improving brain function and method for improving brain function: The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, comprising, as an active ingredient, Phe-Pro.... Agent:

20120077753 - Jnk inhibitors for use in treating spinal muscular atrophy: The brain specific isoform (JNK3) of c-Jun NH2-terminal kinase (JNK) has been found to mediate the degeneration of spinal motor neurons caused by SMN deficiency in spinal muscular atrophy (SMA). Moreover, the ability of JNK inhibitors to reduce degeneration of neurons lacking SMN is also disclosed. The JNK signaling pathway... Agent:

20120077751 - Methods for modulating neuronal responses: The invention provides, in part, methods and reagents for modulating neuronal apoptosis and for modulating synaptic plasticity.... Agent:

20120077754 - Copolymer-1 improvements in compositions of copolymers: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.... Agent:

20120077755 - Compounds for, and methods of, treating cancer and inhibiting invasion and metastases: Invasion-inhibiting peptides comprising either a modified cysteine (where the sulfur atom is modified with a alkyl group or other suitable group), and/or b) D-amino acids, for the treatment “cancer” in humans and animals. Such peptides can be used together with other therapies (e.g. radiation) to enhance the therapeutic benefit and... Agent:

20120077756 - Methods, compositions, and kits for the treatment of ophthalmic disorders: The invention features methods, kits, and compositions for the treatment of ophthalmic disorders. The compositions include a corticosteroid in combination with a non-steroidal immunophilin-dependent immunosuppressant.... Agent: Zalicus Inc.

20120077758 - Infertility associated defb-126 deletion polymorphism: The present application provides diagnostic methods for determining the fertility status of a male individual by evaluating his DEFB-126 phenotypic and genotypic status. The present invention relates to a dinucleotide deletion polymorphism in the protein coding sequence of a DEFB-126 nucleic acid. The amino acid sequence of this variant has... Agent: The Regents Of The University Of California

20120077757 - Methods for affecting homology-directed dna double stranded break repair: Disclosed herein are methods and composition for alteration of the presence, activity, or concentration of RNF138. Disclosed methods can be utilized to affect DNA double strand break repair. Methods and compositions can be utilized to alter RNF138 so as to prevent interaction between RNF138 and RAD51D. Specifically, methods can prevent... Agent: University Of South Carolina

20120077759 - 3-3-di-substituted-oxindoles as inhibitors of translation initiation: Compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are described.... Agent: President And Fellows Of Harvard College

20120077761 - Compositions and methods for the prevention and treatment of coronary heart diseases: Disclosed herein are compounds and plant extracts, and methods for preventing or treating heart diseases, including coronary heart diseases. The compounds provided herein can be formulated into pharmaceutical compositions and medicaments that are useful in the disclosed methods. Also provided are the use of the compounds and extracts in preparing... Agent: Generex Pharmaceuticals, Inc

20120077760 - Novel salts of sitagliptin: The present invention relates to novel pharmaceutically acceptable salts of sitagliptin, to processes for their preparation and to pharmaceutical compositions containing them.... Agent: Lek Pharmaceuticals D.d.

20120077762 - Compositions and methods for the prevention and treatment of heart failure: Disclosed herein are compounds, extracts, and active fractions of the plant Geum japonicum alone or in combination with Centella Asiatica and methods for preventing or treating heart failure. The compounds provided herein can be formulated into pharmaceutical compositions and medicaments that are useful in the disclosed methods. Also provided are... Agent: Generex Phamaceuticals

20120077763 - Methods for treating heart failure by inhibiting the mitochondrial sodium-calcium exchanger (mnce): Methods and compounds for preventing or reducing the toxic side effects of cardiac glycosides by inhibiting the mitochondrial sodium-calcium exchanger (mNCE) are provided. Methods and compositions for preventing or reducing the occurrence of conditions associated with heart failure, including, but not limited to, sudden cardiac death and contractile decompensation, by... Agent: The Johns Hopkins University

20120077764 - Compositions and method for treating infection in cattle and swine: Novel formulations containing a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as florfenicol, and methods for using such formulations in the treatment and prevention of infectious diseases of bovines and swine, including bovine respiratory disease.... Agent:

20120077765 - Isoxazoline oximes as antiparasitic agents: v

20120077766 - Topical application of ivermectin for the treatment of dermatological conditions/afflictions: Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective... Agent: Galderma S.a.

20120077767 - Molecular predictors of fungal infection: Methods for identifying fungal infection, assays for identifying genomic and protein markers of fungal infection, and methods for diagnosing the fungal infection. In one aspect, the method of identifying fungal infection by proteomic assay involves measuring the protein levels of proteins listed in Table 2A in a peripheral blood cell... Agent:

20120077768 - Stabilized and lyophilized formulation of anthracycline compounds: The present invention provides a lyophilized amrubicin formulation and a process thereof. In the process, the concentration of the aqueous solution before lyophilization is controlled to about 7.5 mg(potency)/mL or more. Thus, the formulation decreases the production of desaccharified compound and is stable to storage for a long period. The... Agent: Daninippon Sumitomo Pharma Co., Ltd

20120077769 - Topical ophthalmic compositions containing tobramycin and dexamethasone: Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so... Agent:

20120077860 - Adeno-associated viral vector for exon skipping in a gene encoding a dispensable domain protein: h

20120077866 - Antisense modulation of c-reactive protein expression: Antisense compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for treatment of diseases associated with expression of C-reactive... Agent: Isis Pharmaceuticals, Inc.

20120077862 - Antisense modulation of ptp1b expression: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.... Agent: Isis Pharmaceuticals, Inc.

20120077861 - Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same: Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.... Agent: The University Of British Columbia

20120077867 - Compositions and methods for treating pancreatic cancer: The present invention provides a method of treating pancreatic cancer by inhibiting the activity cyclin D1 activity in tumor cells. The invention is based on the finding that cyclin D1 shRNA molecules are capable of attenuating tumor growth and interfering with tumor angiogenesis.... Agent: Trustees Od Dartmouth College

20120077863 - Guanidino-substituted bi-and polyphenyls as small molecule carriers: A compound of formula I, or a pharmaceutically acceptable salt thereof, wherein —X1, X2 and X3 are each independently where Y is an alkylene, alkenylene or alkynylene group, each of which may be optionally substituted with one or more substituents selected from alkyl, halo, CF3, OH, alkoxy, NH2, CN, NO2... Agent: Ucl Business PLC

20120077865 - Methods for treating hypercholesterolemia: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an... Agent: Isis Pharmaceuticals, Inc.

20120077864 - Rnai-mediated inhibition of gremlin for treatment of iop-related conditions: RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.... Agent: Alcon Research, Ltd.

20120077870 - Materials and methods for the treatment of pathological neovascularization in the eye: The subject invention provides materials and methods useful in safely and effectively preventing pathological proliferation of blood vessels. The prevention of the over-proliferation of blood vessels according to the subject invention is particularly advantageous for treatment of certain ocular conditions including age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and... Agent:

20120077869 - Method and composition using a dual specificity protein tyrosine phosphatase as an antimalarial drug target: Phosphotyrosine phosphatase (PTP) encoded by PF13_0027 is a desirable drug target for the human malaria parasite Plasmodium falciparum. This PTP is critical for intraerythrocytic parasite development and invasion of erythrocytes by malaria merozoites. Mutation of the PF13_0027 gene or blocking expression of PTP function to create a PTP-null parasite severely... Agent: University Of South Florida

20120077868 - Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders: The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.... Agent:

20120077771 - Compositions for use in cardioplegia comprising esmolol and adenosine: The invention related to a composition for use in cardioplegia, said composition comprising (i) esmolol; and (ii) adenosine, wherein in use the concentration of said esmolol is in the range 0.3-1.5 mM, and wherein in use the concentration of said adenosine is in the range 0.1-1.5 mM. The invention also... Agent: King's College London

20120077770 - Methods of diagnosing and treating multiple sclerosis: Methods of using a 15-oxysterol, e.g., 15-ketocholestene (15-KE), 15-ketocholestane (15-KA), and/or 15-hydroxy-cholestene (15-HC), as a biomarker to monitor disease progression in multiple sclerosis (MS), and methods of treating secondary progressive MS (SPMS) using inhibitors of poly(ADP ribose) polymerase-1 (PARP-1).... Agent: The Brigham And Women's Hospital, Inc.

20120077772 - Solid oral dosage forms of lamivudine: The present invention relates to the oral solid pharmaceutical composition comprising lamivudine or a pharmaceutically acceptable salt thereof with isomalt as a filler. The present invention also relate to the combination of lamivudine and other Anti-HIV agents. Thus, for example, the present invention provides a stable tablet formulation comprising lamivudine,... Agent: Hetero Research Foundation

20120077773 - Use of a composition for the treatment of mucositis: A composition having an ionic complex of chitosan and a negatively charged polysaccharide, selected from the group consisting of heparin, heparan sulfate and dextran sulfate, for use in the treatment of mucositis in a mammalian subject, to a method of preventing or treating mucositis in a mammalian subject, by applying... Agent: Exthera Ab

20120077774 - Compositions and their use for removing cholesterol: The invention is directed to compositions that function to remove cholesterol from a mammal suffering from an elevated cholesterol level. The composition includes a polysaccharide having attached thereto at least one cyclic oligosaccharide. In a particular embodiment, the foregoing composition further includes at least one cell-targeting agent. The invention is... Agent: Cornell University

20120077776 - Hydrolysis resistant organomodified trisiloxane surfactants: are described wherein the substituents on the differing M and M′ groups, in conjunction with pendant polyalkylene oxide substituents on the D group render the surfactant resistant to hydrolysis under either basic or acidic conditions outside the pH range of 6.0 to 7.5. The compositions are useful in agricultural, household... Agent: Momentive Performance Materials Inc.

20120077775 - Macrocyclic compounds useful as inhibitors of kinases and hsp90: Disclosed are macrocyclic compounds of formulae I-V, which are analogs of the pochonin resorcylic acid lactones, and processes for the preparation of the compounds. The compounds disclosed are useful as inhibitors of kinases and Heat Shock Protein 90 (HSP 90). Also disclosed are pharmaceutical compositions comprising an effective kinase-inhibiting amount... Agent: Universite De Strasbourg

20120077777 - Ngcycloartanone derivatives with anticancer activity: s

20120077779 - Inhibitors of fibroblast activation protein alpha: Disclosed are peptide-based compounds that include boronic acid or cyano functionality, which efficiently and selectively inhibit fibroblast activation protein alpha. Among other therapeutic utilities, the peptide-based compounds may be useful for the treatment of cancer.... Agent: Trustees Of Tufts College

20120077778 - Ladder-frame polyether conjugates: Disclosed are compounds that are conjugates of ladder frame polyether compounds and biologically active compounds or research compounds, pharmaceutical formulations comprising the conjugates, and methods of transporting the conjugates across biological membranes.... Agent:

20120077780 - Fat accumulation inhibitor and method of use thereof: The present disclosure relates to a method of inhibiting a fat accumulation for a fat cell in a subject, which includes administering a fat accumulation inhibitor for a fat cell which includes a milk-derived phospholipid as an active ingredient to the subject. The present disclosure also relates to a method... Agent:

20120077781 - Flavin derivatives: The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.... Agent:

20120077782 - Method of activation of oxazaphosphorines: The present invention provides a method of hydroxylating or oxidizing a compound of interest in a subject (e.g., a cytotoxic oxazaphosphorine prodrug), by administering the compound of interest to the subject; and concurrently administering the subject a metalloporphyrin in an amount effective to hydroxylate or oxidize the compound of interest... Agent: Duke University

20120077783 - Materials and methods for treatment and diagnosis of disorders associated with oxidative stress: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema.... Agent: Therapeutic Research LLC

20120077784 - Skin treatment compositions: The present invention relates to compositions, kits and methods for treating skin at sites of concerns such as infectious lesions and/or points of insertion of an insertable medical device to prevent contamination such as infections or protein absorption that may interfere with the function of the device. The composition can... Agent: Ex-tex LLC

20120077785 - Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea;... Agent: Action Medicines

20120077786 - Methods and compositions for disease treatment using inhalation: Methods and compositions for the treatment of pulmonary disease using inhalation are provided. In particular, the present disclosure provides novel methods and compositions for treating pulmonary diseases such as asthma, bronchitis, COPD, emphysema, lung cancer, pneumonia and pulmonary edema. In addition, the present disclosure provides novel methods and compositions for... Agent:

20120077787 - Organic compounds: t

20120077788 - Use of telocinobufagin as an analgesic in the treatment of acute and chronic pains; pharmaceutical composition containing telocinobufagin and its use: The present invention is directed to the use of telocinobufagin, or its pharmaceutically acceptable derivatives, in the manufacture of a medicament for the treatment or prevention of acute and chronic pains. The present invention also refers to a pharmaceutical composition comprising an effective amount of telocinobufagin; also provides a method... Agent: Cristalia Produtos Quimicos Farmaceuticos Ltda.

20120077789 - Method for treatment of diseases: The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering... Agent: Dmi Acquisition Corp.

20120077791 - Novel crystalline form of antiprogestin cdb-4124: The present invention relates to novel crystalline Form A of 17α-acetoxy-21-methoxy-11β-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione, (also known as CDB-4124) and methods for the preparation of it in excellent purity.... Agent:

20120077790 - Ulipristal acetate tablets: The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent... Agent: Laboratoire Hra Pharma

20120077792 - Lanthanide metal complexes useful in treating cancer: The present invention relates to a compound of formula (I). Provided is also a method of killing a cell that comprises administering the compound of formula (I). Provided is also a method of treating cancer or diabetes in a mammal that comprises administering the compound of formula I and respective... Agent: National University Of Singapore

20120077795 - Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists: The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes.... Agent: Glaxsmithkline LLC

20120077798 - Azetidine and cyclobutane derivatives as jak inhibitors: The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.... Agent:

20120077797 - Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors: e

20120077796 - Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy:

20120077794 - Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists: The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes.... Agent: Glaxsmithkline LLC

20120077793 - Compounds for the treatment of metabolic disorders: The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.... Agent: Prosidion Limited

20120077799 - Heterocyclic compound and use thereof: e

20120077800 - Methods for treating antipsychotic-induced weight gain: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in... Agent: Alkermes, Inc.

20120077801 - Chemical compounds 637: e

20120077802 - Histamine h3 inverse agonists and antagonists and methods of use thereof: Provided herein are spiro-cyclic compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of... Agent: Sunovion Pharmaceuticals Inc.

20120077803 - Uses of nk receptor antagonists: o

20120077804 - Small molecule inhibitors of rna silencing: The present invention provides compositions and formulations that contain active compounds as RNAi inhibitors. These compositions and formulations are useful for controlling insects and pests including mosquitoes and agricultural pests.... Agent: The Regents Of The University Of California

20120077805 - Unsolvated benzodiazepine compositions and methods: The present invention relates to systems and methods for generating new forms of benzodiazepine and benzodiazepine related compounds as well as new compounds and formulations generated by such methods. In particular, the present invention provides high throughput systems and methods for generating and identifying new crystalline benzodiazepine and benzodiazepine related... Agent: The Regents Of The University Of Michigan

20120077806 - Deubiquitinase inhibitors and methods for use of the same: Disclosed herein are methods of inhibiting a deubiquitinase (DUB), methods of treating pathogenic infections (e.g., viral, bacterial, and/or parasitic), methods of inhibiting cell proliferation, methods of treating a neurodegenerative disease, methods of treating one or more symptoms of a neurodegenerative disease or a genetic disorder, and compounds.... Agent: The Regents Of The University Of Michigan

20120077807 - Niacin mimetics, and methods of use thereof: Disclosed are 6-(morpholinoalkyl)-substituted pyridines, and pharmaceutically acceptable salts and prodrugs thereof, that are active against a range of mammalian therapeutic indications.... Agent: Trustees Of Tufts College

20120077808 - Niacin mimetics, and methods of use thereof: Disclosed are heterocyclylalkyl-substituted and heteroaralkyl-substituted pyridines, and pharmaceutically acceptable salts and prodrugs thereof, that are active against a range of mammalian therapeutic indications.... Agent: Trustees Of Tufts College

20120077810 - Inhibitors of akt activity: The instant invention provides for substituted fused pyrimidine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient... Agent:

20120077809 - Pyrimidopyridazine derivatives useful as p38 mapk inhibitors: A compound formula (IA) or (IB), or a pharmaceutically acceptable thereof; wherein the substituents are defined as in the claims, and their use as P38 MAP kinase.... Agent: Chiesi Farmaceutici S.p.a.

20120077811 - Prodrug forms of kinase inhibitors and their use in therapy: c

20120077812 - Bicyclic compounds and use as antidiabetics: The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.... Agent:

20120077813 - Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase-3 related disorders such as alzheimer's disease: The present invention relates to a new compound of formula (I) wherein R1 is hydrogen or fluoro; R2 and R3 are independently selected from hydrogen or methyl; or a pharmaceutically acceptable salt thereof, pharmaceutical formulations containing said compound, to the use of said active compound in therapy, to the use... Agent: Astrazeneca Ab

20120077814 - Sulfonamide, sulfamate, and sulfamothioate derivatives: e

20120077815 - Fused pyridine and pyrazine derivatives as kinase inhibitors: A series of amino-substituted fused pyridine and pyrazine derivatives, in particular amino-substituted quinoline and quinoxaline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.... Agent: Ucb Pharma S.a.

20120077816 - Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors: The present invention is related to heterocycles represented by a compound of Formula I that are novel allosteric modulators of α7 nAChRs and/or GABAA receptors. The invention also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on α7 nAChRs and negative allosteric modulation of GABAA... Agent:

20120077817 - Novel pharmaceutical compositions of ranolazine: A novel controlled release pharmaceutical dosage form comprising a therapeutically effective amount of ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof, one or more lipid(s) as release controlling agent(s) and one or more pharmaceutically acceptable excipient(s).... Agent: Lupin Limited

20120077818 - Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof: Provided herein are methods of and compositions for, treating, preventing and managing various neurological disorders. The methods comprise administering a transnorsertraline in combination with a serotonin receptor IA agonist, antagonist or modulator.... Agent: Sunovion Pharmaceuticals Inc.

20120077819 - Use of kinase inhibitor for the treatment of thymoma: The invention provides a low molecular weight ATP-competitive CDK inhibitor and TRKA inhibitor of formula (I) for use in the treatment of thymoma and thymic carcinoma. The compound can be administered together with one or more cytotoxic or cytostatic agents.... Agent: Nerviano Medical Sciences S.r.l.

20120077820 - Compounds and method for treatment of cancer: e

20120077821 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.... Agent: Otsuka Pharmaceutical Co., Ltd.

20120077823 - Controlled release systems of pluribioactive antifungal drugs and applications thereof: Controlled release systems release at least one pluribioactive antifungal drug exhibiting at least one additional bioactivity from the group consisting of spermiostatic, antineoplastic, antibacterial, antirestenotic and antiviral activities. The drug release system is designed for use as a spermiostatic contraceptive, intravaginal ringed-mesh which may also exhibit antiviral activity, an in... Agent:

20120077822 - In situ-formed bioactive tissue adherent films of absorbable crystallizable polymers: An in situ film-forming sprayable methyl acetate-based solution of at least one absorbable, low-crystallinity, segmented copolymer contains at least one bioactive agent, which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane and the bioactive solution thereof can... Agent:

20120077824 - Itraconazole formulations: Provided herein is a pharmaceutical injectable formulation of itraconazole (10 mg/g) where the formulation comprises a solubilizer, a nonionic surfactant/emulsifier, a co-surfactant and a stabilizer. Further provided is a pharmaceutical formulation of itraconazole, said formulation comprising a solubilizer in a concentration of from about 20% to about 75%, a nonionic... Agent:

20120077825 - Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts: 1-[4-(5-cyanoindo1-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof is used for the manufacture of a medicament for the treatment of sub-type anxiety disorders chosen from the sub-types panic disorder with or without agoraphobia, agoraphobia. obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder, bipolar disorders, mania,... Agent: Merck Patentgesellschaft

20120077826 - [6,5] - bicyclic gpr119 g protein-coupled receptor agonists: [

20120077827 - Zap-70 active compounds: Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more protein kinases, including a Zeta-chain-associated protein kinase 70... Agent: Plexxikon, Inc.

20120077828 - Chemical compounds: The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, ocular diseases, and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, Type 1 diabetes Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, atherosclerosis, and... Agent:

20120077830 - Caspase inhibitors and uses thereof: where R1, R2, and R3 are as described herein, Ring A contains zero to two double bonds, each X is independently selected from nitrogen or carbon, at least one X in Ring A is a nitrogen, Ring A is optionally substituted as described, and may be fused to a saturated... Agent: Vertex Pharmaceuticals Incorporated

20120077829 - Parenteral solutions containing metolazone: Disclosed herein are parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamide in N,N-dimethylactamide, polyethylene glycol and D5W useful in the treatment of hypertension, heart failure and renal disease leading to edematous states. Also disclosed are methods for preparing such solutions.... Agent: Academic Pharmaceuticals Incorporated

20120077831 - Methods and assays for the treatment of irritable bowel syndrome: Methods of treating irritable bowel syndrome (IBS) are disclosed. Assays and kits useful in the treatment of IBS are also disclosed.... Agent:

20120077833 - Acid addition salts of (3,5-bis trifluoromethyl)-n-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide: t

20120077832 - Besylate salt of a btk inhibitor: The present invention provides a salt form, and compositions thereof, useful as an inhibitor of one or more protein kinases and which exhibits desirable characteristics for the same.... Agent: Avila Therapeutics, Inc.

20120077834 - Methods of use of cyclopamine analogs: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:... Agent:

20120077835 - Formulations of rifaximin and uses thereof: The present invention relates to new rifaximin forms comprising solid dispersions of rifaximin, methods of making same and to their use in medicinal preparations and therapeutic methods.... Agent: Salix Pharmaceuticals, Ltd.

20120077836 - Methods of administering (4ar,10ar)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo [g] quinoline-6,7-diol and related compounds across the oral mucosa, the nasal mucosa or the skin and pharmaceutical compositions thereof: Disclosed are pharmaceutical compositions and methods for the administration of (4aR,10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol or a pharmaceutically acceptable salt thereof and related compounds for the treatment of neurological disorder such as Parkinson's disease and restless leg syndrome.... Agent: H. Lundbeck A/s

20120077837 - Anti-tumor agent: s

20120077838 - Beta-2-adrenoreceptor agonists:

20120077839 - Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto: wherein R1 is as defined herein, including stereoisomers and pharmaceutically acceptable salts and solvates thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use in a subject in need thereof.... Agent: Neurocrine Biosciences, Inc.

20120077840 - Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors: The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.... Agent: Abbott Gmbh & Co. Kg

20120077841 - Methods for cancer therapy and stem cell modulation: In the general formula A is C or N. R1, R4 and R5 are, independently selected, H or aliphatic, cycloaliphatic, aromatic, arylaliphatic, or arylcycloaliphatic hydrocarbyl groups, that comprise 0-3 heteroatoms being N, O, S, or Si. R4 and R5 may optionally be linked so as to define an aliphatic hydrocarbyl... Agent: Agency For Science, Technology And Research

20120077842 - Quinoline derivative-containing pharmaceutical composition:

20120077843 - Malignant precursor cells from ductal carcinoma in situ lesions: Described herein are progenitor cancer cells and cell lines isolated from human breast ductal carcinoma in situ (DCIS) lesions and the uses of these cells or cell lines in drug design, drug screening, and monitoring in vivo therapy. The DCIS malignant precursor cells or cell lines are epithelial in origin,... Agent: George Mason Intellectual Properties, Inc.

20120077844 - Use of piperidine derivatives as dermo-decontracting agents: s

20120077845 - Estrogen receptor ligands and methods of use thereof: The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, and castration-resistant prostate cancer (CRPC) and palliative... Agent:

20120077846 - Treatment of renal cell carcinoma: Methods are provided of treating renal cancer by administration of certain 3,3′,4,4′-tetrahydroxy-2,2′-bipyridine-N,N′-dioxide compounds, especially 3,3′,4,4′-tetrahydroxy-2,2′-bipyridine-N,N′-dioxide (Orellanine), using particular administration protocols and dosing regimens, as well as pharmaceutical compositions suitable for use in the treatment methods that are provided.... Agent:

20120077847 - Alpha-ketoamide derivatives useful endothelial lipase inhibitors: The present invention is directed to α-ketoamide derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by endothelial lipase, for example, cardiovascular disorders.... Agent:

20120077848 - Novel process to prepare pioglitazone via several novel intermediates: A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine.... Agent: Cadila Healthcare Limited

20120077849 - Inhaler for delivering a metered dose: An inhaler for delivering a metered dose of a medicament, the inhaler comprising a dispensing port (15) and one or more containers (1, 2) holding a combination of a first drug and a second drug; wherein the first drug is for treatment of a physiological condition, and the second drug... Agent: Pragmatic Innovation Limited

20120077850 - Pirfenidone treatment for patients with atypical liver function: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at... Agent: Intermune, Inc.

20120077851 - Urea derivatives as kinase inhibitors: The present invention is directed to novel ureas, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof which are useful for the treatment of protein kinases mediated diseases and conditions. The compounds of this invention have a general Formula (I) wherein R, R1 to R10 are defined herein.... Agent: Medolution Limited

20120077852 - Hydroxypyridinones for the local treatment of skin microcirculatory disorders: The application of hydroxypyridonone in effective amounts as external agent for patients suffering from skin micro-circulatory disorders (SMD) provides for a significant amelioration of subject conditions. Accordingly, the new use of hydroxypyridonones as external anti-inflammatory agent thereby combined with the depletion of hemosiderin residues offers a suitable treatment to SMD... Agent:

20120077853 - Human protein tyrosine phosphatase inhibitors and methods of use: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising one or more human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.... Agent:

20120077854 - Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4): The present invention relates to compositions and methods for modulating retinol binding to retinol binding protein 4 (RBP4). In particular, the present invention provides compounds having Formula (1) or (2) (Formulae (1), (2)); wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, Y4 and m are as defined above.... Agent:

20120077855 - Crystalline tripeptide epoxy ketone protease inhibitors: The disclosure features crystalline tripeptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions.... Agent:

20120077856 - Pharmaceutical product: e

20120077858 - Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response:

20120077857 - Inhibition of inflammation bysimultaneous blockade of multiple prostanoid receptors: wherein R is H or lower alkyl, R1 is hydrocarbyl or substituted hydrocarbyl and the broken line represents a saturated or unsaturated bond, i.e a double bond. Preferably, R1 is an alkyl. More preferably, R1 is a n-alkyl or a cycloalkyl-n-alkyl, e.g. a cyclohexyl-n-alkyl, e.g. n-octyl, n-nonyl or cyclohexyl-n-butyl radical... Agent: Allergan, Inc.

20120077859 - C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers: The present embodiment of the invention is generally directed to compositions comprising suspensions of poorly water soluble compounds recrystallized in nanoparticulate sizes ranging from 0.1 to 5 μm. In addition, the embodiment of the invention is directed to methods for preparation and administration of these compositions to a patient for... Agent: Texas A&m University System, The

20120077871 - 9, 10-alpha, alpha-oh-taxane analogs and methods for production thereof: with a second compound of generalized formula R8R9C(OCH3)2 and an acid selected from the group consisting of camphor sulfonic acid (CSA), p-toluene sulfonic acid (PTSA), hydrochloric acid (HCl) and acetic acid (AcOH), wherein R1 and R2 are each selected from H, an alkyl group, an olefinic group, an aromatic group,... Agent: Tapestry Pharmaceuticals, Inc.

20120077872 - Preservative-free pharmaceutical tetrahydrolipstatin compositions: This invention refers to pharmaceutical compositions that comprise the mixture of an effective amount of leucine-derivative powders or granules and, at least, one pharmaceutically acceptable excipient substance used as carrier. In particular, the main feature of the pharmaceutical composition is the fact that it is free of preservative agents and... Agent: Ems S.a.

20120077875 - Composition including at least one trans-cinnamaldehyde and the use thereof in the treatment of bacterial infections, specifically in the treatment of nosocomial infections: The present invention relates to a composition, in particular an antibacterial drug, including trans-cinnamaldehyde, a pharmaceutical composition including trans-cinnamaldehyde for treatment or prevention, in particular, of a nosocomial infection, specifically caused by a bacteria resistant to anti-bacterial drugs, the use of trans-cinnamaldehyde as an anti-bacterial agent and a method for... Agent: Septeos

20120077874 - Development of a phytoestrogen product for the prevention or treatment of osteoporosis using red clover: A phytoestrogen blend was developed using a pharmaceutical platform technology to identify the time course of active components and effect time course of these components in the biophase after administration of a red clover extract. This phytoestrogen blend consists of biochanin A, daidzein, equol and genistein. The recommended daily dosage... Agent:

20120077873 - Methods of reducing blood lactate concentration: The present invention is directed to methods for reducing blood lactate concentration during exercise, physical activity or athletic performance.... Agent: Stokely-van Camp, Inc.

20120077876 - Method for improved bioactivation of pharmaceuticals: This invention relates to a prodrug comprising a partial structure having the general formula (I) or (II), where R1 and R2 are hydrogen, alkyl, or aryl radicals.... Agent: Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg

20120077877 - Medium chain peroxycarboxylic acid compositions: The present invention relates to compositions including medium chain peroxycarboxylic acid, methods for making these compositions, and methods for reducing the population of a microorganism. The compositions can include advantageously high levels of the medium chain peroxycarboxylic acid, can be readily made, and/or can exhibit reduced odor.... Agent: Ecolab Usa Inc.

20120077878 - Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract: Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression,... Agent: Depomed, Inc.

20120077879 - Process for making compositions with poorly compressible therapeutic compounds: A process for preparing solid dosage forms that contain poorly compressible therapeutic compound. The process, for example, provides for the inventive use of an extruder, especially a twin screw extruder, to melt granulate a therapeutic compound(s) with a granulation excipient.... Agent:

20120077880 - Highly concentrated, spherical biopolymer gel particle suspensions prepared by hipe-gelation process: The invention relates to highly concentrated, spherical, biopolymer gel particle suspensions comprising particle of defined particle diameter range (e.g., 1 to 50μ) and process for preparing the suspensions utilizing high internal phase emulsion as intermediate.... Agent: Conopco, Inc., D/b/a Unilever

20120077881 - Hipe-gelation process for making highly concentrated, spherical biopolymer gel particle suspensions: The invention relates to process for making highly concentrated, spherical biopolymer gel particle suspensions comprising particles of defined particle diameter (e.g., range of 1 to 50μ) utilizing high internal phase emulsion as an intermediate.... Agent: Conopco, Inc., D/b/a Unilever

20120077882 - Antibacterial agent-comprising powders and methods for manufacturing the same: Skin and surface sanitizers and methods for forming skin and surface sanitizers are provided. In one embodiment, a surface sanitizer is formed of a plurality of dry particles. Each dry particle comprises a liquid comprising an antibacterial agent and a dry particulates coating surrounding the liquid. The liquid is present... Agent: The Dial Corporation

20120077883 - Treatment of tinnitus and associated auditory dysfunctions: The invention provides cyclobenzaprine for use in the treatment of tinnitus and related auditory dysfunctions by oral administration as tablets, capsules, powder or a solution or by parenteral administration of cyclobenzaprine through intramuscular, intravenous, subcutaneous or intrathecal injection, or infusion, preferably in an amount from 15 to 45 mg/day, preferably... Agent:

20120077884 - Coccidiosis controlling agent and feed containing the same: An object of the present invention is to provide: a coccidiosis controlling agent which is excellent in safety, is free of problems such as side-effects, does not cause effect reduction or the like due to the acquisition of resistance to a medicament, and exhibits a high preventive effect and a... Agent:

20120077885 - Gelling agent and gel: wherein n and m are each independently an integer of 2 to 18, R1 and R3 are each independently a single bond or a branched or linear alkylene group having 1 to 6 carbon atoms, R2 is a branched or linear alkylene group having 3 to 18 carbon atoms, and... Agent:

20120077886 - Hydrophilic polyproylene melt additives: Melt additive ionic and non-ionic surfactants to impart stable durable hydrophilicity to thermoplastic polymers or blends thereof.... Agent:

20120077887 - Terpolymers as pressure-sensitive adhesives: Disclosed herein are terpolymers that can function as pressure-sensitive adhesives. The disclosed articles comprise the terpolymers adhered to a release liner. The disclosed implant devices comprise the pressure-sensitive adhesive terpolymer adhered to a surface thereof. The pressure-sensitive adhesive terpolymer can promote adhesion of the implant device to a location in... Agent:

20120077888 - Orodispersible tablets: A directly compressed orodispersible tablet comprises 0.1 to 50% of a ungranulated active agent (w/w), 10 to 80% of a sugar-based direct compression base, and 10 to 80% of a microcrystalline cellulose (MCC) direct compression base, and has a hardness of at least 60N, and a disintegration time of less... Agent: Royal College Of Surgeons In Ireland

  
03/22/2012 > 178 patent applications in 135 patent subcategories. listing by industry category

20120071393 - Mutant cyaa polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell: The invention is more particularly directed to polypeptides derived from an adenylate cyclase protein (CyaA) either under the form of a toxin or of a toxoid, which are mutant polypeptides. Said mutant polypeptides are capable of retaining the binding activity of native CyaA to a target cell and preferably of... Agent:

20120071394 - Novel polypeptides and use thereof: The present invention provides a polypeptide having a biological activity of the Chemotaxis Inhibitory Protein of Staphylococcus aureus (‘CHIPS’), the polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 2, or a fragment or variant thereof having a biological activity of CHIPS, wherein the fragment or... Agent:

20120071395 - Treatment of mammalian physiological reaction of ige antibodies present in said mammal upon contact with the correspondeing antigen: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.... Agent:

20120071396 - Compositions and methods for inhibiting the interaction between cftr and cal: The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same... Agent: Trustees Of Dartmouth College

20120071397 - Methods for hematopoietic stem cell transplantation: The present invention provides methods for treating a subject undergoing hematopoietic stem cell transplantation, methods for increasing a subject's resistance to bacterial or viral infection during and/or following hematopoietic stem cell transplantation, and methods for treating norovirus infection.... Agent: University Of Southern California

20120071398 - Anti-microbial peptides: wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, together with methods for the use of the peptides in the treatment... Agent: Novabiotics Limited

20120071400 - Lipid metabolism-improving reagent: Our objective is to provide a novel lipid metabolism-improving reagent effective in preventing and treating hyperlipidemia and obesity and to provide this reagent in food, beverages, nutritional supplements, and fodders with the ability to improve lipid metabolism. The whey protein hydrolysate as the active ingredient in the lipid metabolism-improving reagent... Agent: Megmilk Snow Brand Co., Ltd.

20120071399 - Sulfation of wnt pathway proteins: Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or... Agent: Enzo Biochem, Inc.

20120071401 - Amylin agonist compounds for estrogen-deficient mammals: Provided herein are methods to treat estrogen deficiency in mammals by administering amylin agonist compounds. Also provided herein are methods to treat obesity and overweight in estrogen-deficient mammals; methods to reduce or maintain body weight and/or body fat in estrogen-deficient mammals; and methods to increase Bdnf levels in mammals by... Agent: Amylin Pharamaceuticals, Inc.

20120071403 - Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof: The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or... Agent: Bristol-myers Squibb Company

20120071402 - Protease stabilized, pegylated insulin analogues: Novel PEGylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. The PEGylation is at B29K.... Agent: Novo Nordisk A/s

20120071404 - Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds: The present invention provides for a method for stimulating the proliferation of pluripotential stem cells in a mammal comprising administration of pregnancy related compounds more particularly human chorionic gonadotropin, leutenizing hormone or prolactin. The present invention further provides for a method of treatment of tissues or organs experiencing cellular damage,... Agent: Stem Cell Therapeutics Corp.

20120071405 - Composition of inhibiting pathological angiogenesis: The present invention provides a pharmaceutical composition for inhibiting pathologic angiogenesis and/or cell proliferative disorder. The pharmaceutical composition of the present invention comprises an effective amount of LECT2 protein or analogue thereof, and a pharmaceutically acceptable carrier.... Agent: Tty Biopharm Company Limited

20120071406 - Modified vegf-a with improved angiogenic properties: The present invention is directed to methods and compositions for making and using chimeric polypeptides that comprise a VEGFR-2 ligand. The chimeric molecules of the present invention retain VEGFR-2 binding activity and an enhanced angiogenic activity as compared to native VEGF-A.... Agent: Vegenics Pty Limited

20120071407 - Method of treating wounds: A novel method of treating a wound is provided. The method comprises administering a therapeutically effective amount of periostin to the wound.... Agent:

20120071408 - Formulations for achieving weight loss: A formulation of human chorionic gonadotropin (HCG) for promoting weight loss comprising reconstituted HCG in an amount sufficient to promote weight loss; at least one vitamin selected from the group consisting of: vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, and vitamin B12; and... Agent:

20120071409 - Colloidal liposomal compositions and methods: A formulation delivery system is disclosed. When configured as a pro-liposome oral tablet, the tablet comprises a blend of at least one Iiposome forming ingredient, at least one active ingredient and at least one co-disintegrant. After ingestion at least a portion of the tablet disintegrates in a portion of an... Agent:

20120071410 - Calcitonin products and therapies for treating inflammatory or degenerative diseases: Calcitonin products and therapies for treating inflammatory or degenerative diseases are disclosed herein. The pharmaceutical compositions disclosed herein include a first therapeutic agent that is calcitonin, in free or salt form; a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent,... Agent: Unigene Laboratories Inc.

20120071411 - Lkktet and/or lkktnt peptide compositions which are lyophilized or in a form capable of being lyophilized: A composition including a peptide agent including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2], a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2] peptide, or a conservative variant... Agent: Regenerx Biopharmaceuticals, Inc.

20120071412 - Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed... Agent:

20120071413 - Treatment of chronic nephropathies using soluble complement receptor type i (scr1): A method is disclosed for treating nephropathies involving undesired alternative pathway complement activation by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1).... Agent:

20120071414 - Method for producing and using active principles of limestone: The present invention relates to a method for extracting organic molecules and/or organic minerals from a limestone material, including placing said limestone material in contact with a solution including at least one organic solvent, water and at least one acid, as well as to the organic molecules and/or organic minerals... Agent: Museum National D'histoire Naturelle

20120071415 - Dominant negative mutants of sam68 for use in the treatment of spinal muscular atrophy (sma): The present invention relates to the use of dominant negative mutants of Sam68 for the manufacture of a medicament for the treatment of spinal muscular atrophy, to nucleic acids coding for such mutants and to vectors and methods related thereto.... Agent: Fondazione Santa Lucia

20120071416 - Low frequency glatiramer acetate therapy: A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three... Agent: Teva Pharmaceutical Industries, Ltd.

20120071418 - Inhibitors of human ezh2 and methods of use thereof: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2,... Agent: Epizyme, Inc.

20120071417 - Methods of inhibiting cancer cell growth with hdac inhibitors and methods of screening for hdac10 inhibitors: Methods of inhibiting cancer cell growth using HDAC10 inhibitors are provided. Methods of treating cancer in a subject using HDAC10 inhibitors are also provided. In certain embodiments, at least one second inhibitor selected from an autophagy inhibitor, an AMPK inhibitor, and methyl pyruvate is also used in the methods. Dose... Agent:

20120071420 - Modified t cell receptors and related materials and methods: The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services

20120071419 - Target-specific non-antibody protein and method for preparing the same: The present invention relates to a method for preparing a target-specific non-antibody protein, and more particularly, to a method for preparing a target-specific non-antibody protein comprising the steps of: selecting non-antibody proteins having a structural complementarity with the target site of a target protein in a non-antibody protein library; calculating... Agent: Postech Academy-industry Foundation

20120071421 - Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer: The invention discloses high levels of receptors for Clostridium perfringens enterotoxin (CPE) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of CPE is disclosed. High levels of Ep-CAM protein is also... Agent: Yale University

20120071422 - Therapeutic application of isolated naturally-occuring soluble truncated forms of il-23 receptor: The present invention relates to an isolated naturally-occurring soluble truncated IL-23Rα protein, which is a translated protein resulting from a mRNA splice variant of IL-23Rα. The soluble IL-23Rα proteins (e.g., Δ9 and Δ8,9) represents a novel soluble IL-23Rα protein, which is lacking a transmembrane domain and has a unique eight... Agent: Medical Diagnostic Laboratories LLC

20120071423 - Heterotricyclic ampa receptor antagonists for treatment of epilepsy, pain, and other neurological disorders and diseases: Disclosed are heterotricyclic compounds, pharmaceutical compositions, methods of treatment, and methods for selectively antagonizing a glutamate receptor. The pharmaceutical compositions may include and the methods may utilize heterotricyclic compounds that are glutamate analogues which have specificity for AMPA receptors. The pharmaceutical compositions may be utilized to treat or prevent neurological... Agent: Northwestern University

20120071424 - Pharmaceutical composition used in prophylaxis or treatment of hyperproliferative skin conditions and malignant melanomas comprising pachastrissamine as active ingredient: Disclosed is a novel use of phytosphingosine. More particularly, disclosed are a composition for preventing or treating hyper-proliferative skin diseases comprising pachastrissamine as an active ingredient, a use of pachastrissamine or a pharmaceutically acceptable salt thereof for preparing a preventing/therapeutic agent of hyper-proliferative skin diseases, and a method for treating... Agent: Catholic University Industry Academy Cooperation Foundation

20120071425 - Uses of mannose-6-phosphate: There is provided the use of mannose-6-phosphate, or a salt, precursor or analogue thereof, for providing and/or maintaining a consistent skin colour, particularly to reducing redness of skin. There is also provided the use of mannose-6-phosphate, or a salt, precursor or analogue thereof, as a skin improvement agent for providing... Agent: Renovo Limited

20120071426 - Methods and compositions for treating lung cancer: The present invention provides methods and compositions for treating lung cancer by cyclohexenone compounds.... Agent: Golden Biotechnology Corporation

20120071427 - Novel antidiabetic furostanolic saponin rich (fsr) fraction from fenugreek seeds: The present invention discloses a novel anti-diabetic composition extracted from fenugreek seeds. The same comprises a furostanolic-saponin-rich fraction (>70%) with approximately 30% protodioscin as one of the bioactive components. Pre-clinical studies in rats indicated significant glucose lowering effect of the fraction (31.5%) as compared to control after two weeks of... Agent:

20120071428 - Nanocrystalline photocatalytic colloid, a method of producing it and its use: The present invention relates to a nanocrystalline photocatalyst active upon visible light irradiation, with a high degree of dispersion, stable in the form of a transparent colloidal solution in an aqueous environment, containing nanocrystals of titanium dioxide (TiO2) surface-modified via direct chemisorption of organic compounds. The present invention in turn... Agent:

20120071429 - Novel antibacterial agents: Described herein are novel macrolides, the preparation of novel macrolides, the use of novel macrolides for preventing, treating, or ameliorating various conditions, and the use of novel macrolides as antibacterial agents.... Agent:

20120071430 - Synthetic analogs of bacterial quorum sensors: and methods of reducing bacterial pathogenicity, comprising providing a biological system comprising pathogenic bacteria which produce natural quorum-sensing molecule; providing a synthetic bacterial quorum-sensing molecule having the above structures and introducing the synthetic quorum-sensing molecule into the biological system comprising pathogenic bacteria. Further is provided a method of targeted delivery... Agent: Los Alamos National Laboratory

20120071431 - Platycodin radix extracts, and their use in treating disease conditions associated with angiogenesis: Extracts of radix platycodin are used to inhibit angiogenesis, particularly angiogenesis that is associated with disease conditions other than obesity or cancer.... Agent:

20120071540 - Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer: The present invention provides small interfering RNA (siRNA) molecules, compositions containing the molecules, and methods of using the molecules and compositions to treat breast cancer. In one aspect, a multi-targeted siRNAi cocktail is disclosed. The siRNA molecules may be encapsulated in nanoparticles to further enhance their anti-cancer activity. The compositions... Agent:

20120071539 - Compounds and methods for modulating the silencing of a polynucleotide of interest: Methods and compositions comprising chemical compounds that modulate the silencing of a polynucleotide of interest in a cell are provided. Such chemical compounds when used in combination with an appropriate silencing element can be used to modulate (increase or decrease) the level of the polynucleotide targeted by the silencing element.... Agent: Emory University

20120071541 - Micro-rna associated with rheumatoid arthritis: An object of the present invention is to provide a novel marker for rheumatoid arthritis (RA), and more specifically, to provide a marker whose expression may be specifically increased or decreased in RA. Another object of the present invention is to confirm whether or not miRNA serving as the marker... Agent: National University Corporation Kobe University

20120071542 - Application of highly conserved domain sequences from viral genome as template to design therapeutic slirnas: This invention relates to the application of the highly conserved sequences of viral genome, especially from a highly conserved domain of enteroviral genome as templates to design target small ligand RNAs (sliRNAs). The resulting sliRNAs are therapeutically active ingredients in the treatment of the related diseases caused by pathological angiogenesis.... Agent: Biomics Biotechnologies Co., Ltd

20120071545 - Compositions and methods for treatment of bacterial and mycobacterial infections: A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to... Agent:

20120071543 - Formulations of diluted genetic material and methods for making same: Formulations of highly diluted genetic material are disclosed. The genetic material may be human genetic material that is associated with a health effect in humans. For example, the genetic material may cause, ameliorate, reduce, or otherwise affect any form of illness, disease, and/or overall wellness in humans. The formulations are... Agent:

20120071544 - Methods for identifying compounds effective to increase the expression or activity of aspartyl aminopeptidase in mammalian pancreatic islet cells, and methods for decreasing angiotensin ii levels in mammalian pancreatic islet cells: The methods provided herein are based on the discovery, as described in more detail herein, that aspartyl aminopeptidase (DAP) is expressed in mammalian pancreatic islet cells and that increased DAP expression results in decreased angiotensin II (Ang II) levels in the islet cells. Methods are provided for identifying compounds effective... Agent:

20120071546 - Novel glutamic acid decarboxylase (gad) chimera and methods of use: The invention relates to a novel Glutamic Acid Decarboxylase (GAD). More specifically, novel DNA and protein sequences relating to GAD. Additionally, the invention discloses a novel composition and related methods for treating neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, epilepsy, and the like, using viral and non-viral delivery systems... Agent: Neurologix, Inc.

20120071432 - Central administration of stable formulations of therapeutic agents for cns conditions: The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-ac-Live agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing... Agent: The Regents Of The University Of Colorado

20120071433 - Substituted 6-(benzylamino) purine riboside derivatives, use thereof and compositions containing these derivatives: The invention relates to 2-substituted-6-(substituted benzylamino)purine riboside derivatives of the general formula I. These compounds possess antiapoptotic, anti-inflammatory and differentiating activities. The invention relates also to the compositions, which contain these derivatives as active ingredients.... Agent:

20120071434 - Substituted nucleotide analogs: Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.... Agent: Alios Biopharma, Inc.

20120071435 - Pharmaceutical combinations comprising for the treatment of specific cancers: The present invention relates to the field of oncology and provides compositions and methods for treating specific cancers, including non small cell lung cancer, breast cancer, thyroid cancer, pancreatic cancer, colon cancer, melanoma, hepatoma and adenocarcinoma. Particularly, compositions and methods involving administration, either simultaneously or sequentially, of pharmaceutical combinations comprising... Agent: Ardea Biosciences, Inc.

20120071436 - Method, composition and kit for antigenic binding of norwalk-like viruses: A method for preventing or treating an active Norwalk-Like Virus (NLV) infection in the gastrointestinal (GI) tract of a host, comprising the step of administering orally a fucosyl α1→2 carbohydrate compound to the host, the compound having a binding specificity of the antigenic determinant of a human histo-blood group antigen... Agent:

20120071441 - 6'-sialyllactose salts and process for their synthesis and for the synthesis of other alpha-sialyloligosaccharides: The present invention relates to a process of synthesis of α-sialyl oligosaccharides and in particular of 6′-sialyllactose and its salts comprising a step of coupling by Koenigs-Knorr reaction under conditions that allow its use on an industrial scale.... Agent: Inalco S.p.a.

20120071438 - Antimicrobial compositions containing cationic active ingredients and quaternary sugar derived surfactants: The antimicrobial composition of the present invention comprises a cationic active ingredient, a quaternized sugar-derived surfactant, and an optional foam boosting surfactant. These formulations have a high cidal activity in a short amount of time and provide stable copious foam. The formulations of the present invention also exhibit enhanced tissue... Agent: Ecolab Usa Inc.

20120071439 - Cartilage production promoter and prophylactic or therapeutic agent for diseases associated with cartilage damage: Disclosed is a therapy which is for preventing or treating cartilage damage and diseases associated with cartilage damage, such as arthritides and osteoarthritis, and utilizes a more effective and more safe medicinal agent. Specifically disclosed are a cartilage production promoter, a glucosaminoglycan and/or proteoglycan production promoter, and a prophylactic or... Agent:

20120071442 - Lipid conjugates in the treatment of chronic rhinosinusitis: This invention provides a method of treating, suppressing, inhibiting, or preventing chronic rhinosinusitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical... Agent:

20120071443 - Nanoparticles: Materials and methods for studying and modulating the interaction of carbohydrate-containing moieties with other species are described, in particular, small particles, e.g. clusters of metal or semiconductor atoms, which can be employed as a substrate for immobilising a plurality of ligands comprising carbohydrate groups. These “nanoparticles” can then be used... Agent: Midatech Limited

20120071440 - Pharmaceutical composition for enhancing adiponectin production and food useful therefor: A pharmaceutical product having excellent adiponectin production ability, and food useful for the pharmaceutical product is provided. The pharmaceutical product contains, as active ingredients, a sugar having a polymerization degree of 2-10, wherein mannose units account for not less than 50% based on the number, and a chlorogenic acid.... Agent:

20120071437 - Tunable crosslinked polysaccharide compositions: The present specification generally relates to injectable dermal fillers including multifunctional polyethylene glycol-based crosslinking agents, hydrogel compositions comprising a matrix polymer crosslinked with such crosslinking agents, and methods of treating a soft tissue condition using such hydrogel compositions.... Agent: Allergan, Inc.

20120071444 - Method and composition for the control of ectoparasites: An ectoparasiticidal composition is provided that comprises a mixture of a carrier and an active with an emulsifying agent. The carrier comprises non-volatile low viscosity siloxane and the active comprises a non-volatile high viscosity siloxane. The low viscosity siloxane and the high viscosity siloxane both have a closed cup flash... Agent: Thornton & Ross Limited

20120071445 - Combination therapy for the treatment of multiple myeloma: The present invention provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and bortezomib. The invention further provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a... Agent: Cephalon, Inc.

20120071446 - Dosage regimen of an s1p receptor agonist: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial 3 to 6 days of treatment the daily dosage is raised so that in total the R-fold (R being the accumulation factor) standard daily dosage is administered and thereafter continued at the standard daily dosage... Agent:

20120071447 - Antiviral drugs for treatment of arenavirus infection: P

20120071448 - S1p3 receptor inhibitors for treating conditions of the eye: Disclosed herein are compositions and methods for treating conditions of the eye using S1P3 receptor inhibitors.... Agent: Allergan, Inc.

20120071449 - Pharmaceutical composition for inhalation: The present invention relates to a pharmaceutical composition for inhalation. The invention is further directed to a method for setting the performance characteristics of such a pharmaceutical composition and the use of such a composition in the treatment of asthma, COPD, allergies, infectious diseases and diseases of the cardiovascular system.... Agent: Sanofi Sa

20120071452 - Combinations comprising antimuscarinic agents and corticosteriods: Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic... Agent:

20120071451 - Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid: The present invention is directed to a method for the treatment of nonalcoholic steatohepatitis (NASH) by administering an elevated dose of ursodeoxycholic acid (UDCA), or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment, wherein the patients demonstrate a significantly improved glycemic profile during treatment.... Agent: Aptalis Pharma Canada Inc.

20120071450 - Organic compounds: Optionally substituted 4,5,7,8-tetrahydro-(optionally 4-thioxo or 4-imino)-(1H or 2H)-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-thioxo or 4-imino)-(1H or 2H)-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidine compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.... Agent:

20120071453 - Steroide anionic compounds, method of their production, usage and pharmaceutical preparation involving them: for treatment of various diseases of the central nervous system, in treatment of neuropsychiatric disorders related to imbalance of glutamatergic neurotransmitter system, ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, PTSD and other diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addictions, multiple... Agent:

20120071454 - Steroid compounds and treatment methods: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.... Agent: Harbor Biosciences, Inc.

20120071455 - 6-substituted demethyl-estradiol derivatives as selective er-beta agonists: Disclosed herein are 6-substituted 13-demethyl-estradiol derivatives as selective ERβ agonists. Also disclosed is a method for treating pain by administering these 6-substituted 13-demethyl-estradiol derivatives.... Agent:

20120071456 - Composition: Hair treatment composition comprising a zinc-based antidandruff agent, a conazole fungicide and a cationic modified guar deposition polymer.... Agent:

20120071457 - Metallo-beta-lactamase inhibitors: A new metallo-β-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of β-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-β-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of β-lactam antibiotics against metallo-β-lactamase producing bacteria... Agent:

20120071459 - Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists: The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes.... Agent: Glaxosmithkline LLC

20120071458 - Methods for treating obesity: The invention is directed to methods for treating and/or controlling obesity in a patient. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, AEGR-733 and implitapide) and a cholesterol absorption inhibitor (CAI) (for example, ezetimibe).... Agent:

20120071460 - Pyrazole oxadiazole derivatives as s1p1 agonists: The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases, wherein R1, R2 and R3 are as defined in the description.... Agent: Merck Serono Sa

20120071461 - Substituted benzamide compounds: e

20120071462 - Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them:

20120071463 - Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods: 1H-Imidazo[4,5-c]quinolin-4-amines with a hydroxy, alkoxy, hydroxyalkoxy, or alkoxyalkoxy substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are... Agent: 3m Innovative Properties Company

20120071464 - Method of treatment of obsessive compulsive disorder with ondansetron: Methods for treating obsessive compulsive disorder are described. In one method, a serotonin reuptake inhibitor (SRI) and ondansetron or a pharmaceutically acceptable salt thereof is administered to a patient suffering from obsessive compulsive disorder. The step of administering the SRI and the ondansetron is then repeated for more than seven... Agent:

20120071465 - Mitochondrial activity inhibitors of cancer-initiating cells and use thereof: The present invention relates to the compounds useful in the prevention and/or treatment of tumours. More specifically the present invention relates to inhibitors of the activity of the electron transport chains and/or the mitochondrial TCA cycle in glioma-initiating cells (GICs) for use in a method for preventing and/or treating tumours... Agent: Universite De Geneve

20120071466 - Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1: The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type I (11-beta-HSD1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's... Agent:

20120071467 - Amide derivative: Compounds or pharmacologically acceptable salts thereof are provided. In various embodiments the compounds have an antagonistic effect on a neurokinin NK1 receptor, a neurokinin NK2 receptor, and a muscarine M3 receptor. The compounds are useful as therapeutic agents for bronchial asthma, chronic obstructive pulmonary disease, or the like.... Agent: Daiichi Sankyo Company, Limited

20120071468 - Methods of treating mild cognitive impairment (mci) and related disorders: The invention provides compositions and methods for the treatment of mild cognitive impairment (MCI), and for inhibiting, reducing, delaying and/or preventing the progression of MCI to Alzheimer's disease. The methods entail administering an effective amount of one or more compounds selected from the group consisting of tropisetron, disulfuram, honokiol and... Agent: Buck Institute For Age Research

20120071469 - Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators: This invention relates to novel 1,4-diaza-bicyclo[3.2.1]octane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention... Agent: Neurosearch A/s

20120071470 - Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic: The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and a diuretic and to a method of using such composition for the treatment of cardiovascular disease.... Agent:

20120071471 - Novel benzoxazinone derivatives useful for the treatment of cns disorders: The present invention encompasses novel 1,4-dihydro-3,1-benzoxazin-2-one derivatives, which are surprisingly found to be efficacious in animal models of CNS disorders and, as such, are valuable candidates for the prevention or treatment of CNS (Central Nervous System) diseases or disorders.... Agent: Neurosearch A/s

20120071472 - Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.... Agent: Global Alliance For Tb Drug Development

20120071473 - Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders: e

20120071474 - Inhibitors of pi3 kinase:

20120071476 - Morpholinopurine derivatives:

20120071475 - Urea derivatives having pi3k-inhibiting activity: Provided is a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors,... Agent: Shionogi & Co., Ltd.

20120071477 - Cdki pathway inhibitors and uses thereof: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.... Agent: Senex Biotechnology, Inc.

20120071478 - Substituted benzotriazines and quinoxalines as inhibitors of p7os6 kinase: e

20120071479 - Pyrazine derivatives as enac blockers: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing... Agent: Novartis Ag

20120071480 - 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer: d

20120071481 - Isoxazole-5-carboxamide derivatives: The present invention relates to isoxazole-3-carboxamide derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of said isoxazole-3-carboxamide derivatives for the treatment of TRPV1 mediated disorders, such as acute and chronic pain disorders, acute and... Agent:

20120071482 - Heteroaryl compounds useful as inhibitors of e1 activating enzymes: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.... Agent: Millennium Pharmaceuticals, Inc.

20120071483 - Therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response: The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, the invention relates to combined therapies that modulate cell stress response for treating said disease.... Agent: Pharnext

20120071484 - Topical parasiticide composition: A topical parasiticide composition comprising: (i) a phenyl pyrazole insecticide; and/or a neonicotinoid; (ii) a macrocylic lactone and/or an aminoacetonitrile derivatives; (iii) an Insect Growth Regulator; and (iv) a 2-acyl-4-oxo-1,2,3,6,7,11b-4H-pyrazino[2,1a]isoquinoline derivative.... Agent:

20120071486 - Thienopyrimidine compounds and use thereof: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a hydroxy group, (3′) a C1-4 alkyl and (4′) a C1-4 alkoxy, (2) a phenyl which may have a... Agent: Takeda Pharmaceutical Company Limited

20120071485 - Therapeutic compositions and methods: The present invention relates in general to therapeutic compositions and methods of use. In preferred embodiments, the invention relates to the field of eye health. In some embodiments, the invention relates to the prevention and treatment of macular degeneration by administering compounds disclosed herein. In some embodiments, the invention relates... Agent: The Texas A&m University System

20120071489 - Derivatives of n-acyl-n'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes: The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, which has a superior RBP4-lowering action and is useful as a pharmaceutical composition for the prophylaxis or treatment of a disease or condition mediated by an increase in RBP4.... Agent:

20120071488 - Melting tablet containing a sildenafil salt: The invention relates to an orodispersible tablet comprising the components pharmaceutically acceptable sildenafil salt (a), polymeric adsorbent (b), in particular cation exchanger resin, sweetener (c), and flavoring (d) and, preferably, mucilage (e) and glidant (f). The invention furthermore relates to a process for the preparation of orodispersible tablets comprising a... Agent: Ratiopharm Gmbh

20120071490 - P70 s6 kinase inhibitors: e

20120071491 - Oligomer-protein tyrosine kinase inhibitor conjugates: The invention relates to (among other things) oligomer-PTK inhibitor conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over PTK inhibitor compounds lacking a water-soluble, non-peptidic oligomer.... Agent: Nektar Therapeutics

20120071492 - Oligomer-protein tyrosine kinase inhibitor conjugates: The invention relates to (among other things) oligomer-PTK inhibitor conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over PTK inhibitor compounds lacking a water soluble, non peptidic oligomer.... Agent: Nektar Therapeutics

20120071487 - Piperazine, piperidine and tetrahydropyridine derivatives and their pharmaceutical use: Novel piperazine, piperidine and tetrahydropyridine derivatives comprising a dibenzofurane moiety are provided herein, as well as pharmaceutical compositions comprising same and therapeutic uses thereof.... Agent: Atir Holding S.a.

20120071493 - Substituted 8-sulfonyl-2,3,4,5-tetrahydro-1h-gamma-carbolines, ligands and pharmaceutical composition; method for the production and use of same: v

20120071494 - Pyrazolopyridine kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20120071495 - Treatment for neurological and mental disorders: Methods for treating neurological or mental disorders in humans and the symptoms associated therewith are provided by administering eltoprazine and/or related compounds. In some embodiments, specific symptoms are treated by administering eltoprazine and/or a related compound in an effective amount to ameliorate the symptoms. Of particular significance are symptoms that... Agent: Psychogenics, Inc.

20120071496 - Aminopyrimidinamides as pest control agents: The present application relates to novel aminopyrimidinamides, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.... Agent: Bayer Cropscience Ag

20120071497 - Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase: Disclosed herein are methods for treating an individual diagnosed with ABC-DLBCL. The methods include administering to the individual an inhibitor of Bruton's tyrosine kinase (Btk).... Agent: Pharmacyclics, Inc.

20120071498 - Therapeutic composition to treat lesions caused by herpes simplex virus: The present invention is generally directed toward therapeutic compositions for treating infections caused by Herpes Simplex Virus (“HSV”). The therapeutic compositions meet a long felt need in the art of providing a treatment for lesions that result from HSV that drastically reduce the duration of a cold sore when vesicles... Agent:

20120071499 - Substituted spiro[3h-indole-3,6'(5'h)-[1h]pyrrolo[1,2c]imidazole-1',2(1h,2'h)-diones: e

20120071500 - Macrocyclic lactone compounds and methods for their use:

20120071501 - Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones: The present invention relates to extracts from Cimicifuga species and particularly from Cimicifuga racemosa, which are suited for producing a ready-formulated drug for the selective treatment and/or prophylaxis of sexual hormone-related disorders of the uro-genital tract. The extracts in accordance with the invention are moreover suited for the treatment and/or... Agent: Bionorica Ag

20120071502 - Novel phenoxyisobutyric acid compounds and methods for synthesis: The present invention provides a process for the synthesis of substituted phenoxymethylpropionic acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).... Agent: Cell Viable Corporation

20120071503 - Positive allosteric modulators of group ii mglurs: The disclosure provides compounds and compositions, and methods of using these compounds and compositions, as positive allosteric modulators of the metabotropic glutamate subtype 2 (mGlu2) receptor, and for treating CNS disorders associated with the mGlu2 receptor including schizophrenia, anxiety, addiction, e.g. cocaine addiction, nicotine addiction, and the like.... Agent: Sanford-burnham Medical Research Institute

20120071506 - Methods for treating cns disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles: e

20120071504 - Modulators of cystic fibrosis transmembrane conductance regulator:

20120071505 - Substituted pyridine derivatives, pharmaceutical compositions, and methods of use to treat oxidative stress: Substituted pyridine derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted pyridine derivative, and methods of use in treating inflammation are provided. The substituted pyridine derivatives may control of the activity or the amount or both the activity and the amount of heme-oxygenase.... Agent: High Point Pharmaceuticals, LLC

20120071508 - Cyclic-alkylamine derivatives as inhibitors of the interaction between mdm2 and p53: b

20120071507 - Treatment regimen utilizing neratinib for breast cancer: An extended regimen for treatment of HER-2/neu overexpressed/amplified cancer is described, with involves delivering a course of neratinib therapy to HER-2/neu overexpressed/amplified cancer patients following the completion of surgical and adjuvant therapy. The neratinib regimen may be continued for upwards of twelve months to five years. Also provided are pharmaceutical... Agent: Wyeth LLC

20120071509 - process: The present invention relates to improved processes for preparing 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (I) (lenalidomide) and its intermediate 3-(1-oxo-4-nitro-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione. The present invention further relates to improved processes for preparing lenalidomide crystalline form A, use of said crystalline form A as an active pharmaceutical ingredient or as an intermediate in the preparation of further... Agent:

20120071510 - Method and composition for treating migraines: A method for treating migraines is disclosed. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent, including small molecules and peptides being administered to a patient in need of treatment. In particular, the drug delivery system is designed for inhalation for delivery... Agent: Mannkind Corporation

20120071511 - Fentanyl-containing adhesive preparation for external use: Disclosed is a fentanyl-containing adhesive preparation for external use, wherein an adhesive layer is laminated on a supporting body. The adhesive layer contains SIS, a tackifier resin that is composed of a rosin resin and terpene resin, and a softener that is composed of a plybutene and a liquid paraffin.... Agent:

20120071512 - 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1: s

20120071513 - Compositions and their use as anti-tumor agents: The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not... Agent: Compass Pharmaceuticals LLC

20120071514 - Benzoxazolone derivatives as aldosterone synthase inhibitors: e

20120071515 - Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof: The present invention discloses a nitropyridinyl ethyleneimine compound as shown in the formula I and a preparation method of the same, as well as use of the compound in manufacture of a prodrug and in manufacture of a drug for treating a tumor.... Agent:

20120071517 - 2-pyridinylethylcarboxamide derivatives and their use as fungicides: e

20120071516 - Compounds that modulate intracellular calcium: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel... Agent: Calcimedica, Inc.

20120071518 - Treatment of sepsis with 5-ethyl-1-phenyl-2(1h)-pyridone: A pharmaceutical composition comprising 5-ethyl-1-phenyl-2-(1H)-pyridone (5-EPP) and its use for the treatment of sepsis are disclosed.... Agent: Solanan, Inc.

20120071519 - Crystalline forms of a factor xa inhibitor: Provided herein are crystalline forms of a maleate salt of betrixaban, compositions and methods of preparation or use thereof.... Agent:

20120071520 - Crystalline phases of 2'--biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide: The present invention relates to polymorphic forms and solvates of 2′-{[2-(4-methoxy-phenyl)-acetylamino]-methyl]}-biphenyl-2-carboxylic acid (2-pyhdin-3-yl-ethyl)-amide, processes for their preparation and their use, in particular for the preparation of medicaments.... Agent: Sanofi-aventis Deutschland Gmbh

20120071521 - Concentrated, non-foaming solution of quaternary ammonium compounds and methods of use: A concentrated quaternary ammonium compound (QAC) solution comprising a QAC with a concentration greater than about 10% by weight and at least one solubility enhancing agent, such as an alcohol, is disclosed. A diluted QAC solution is useful on food products to prevent microbial growth on the food from a... Agent: University Of Arkansas

20120071522 - Thermal stabilization of biocides in matrix compositions processed at elevated temperatures: A composition includes (a) a matrix, (b) a biocide, and (c) an antioxidant, in which said biocide exhibits thermal stability at matrix processing temperatures up to 250° C.... Agent: Isp Investments Inc.

20120071523 - Benzofuran-4,5-diones as selective peptide deformylase inhibitors: The instant invention provides novel benzofuran-4,5-diones and pharmaceutical compositions thereof useful for inhibiting PDF and for treating proliferative and infectious diseases. Compounds may be selective for eukaryotic (e.g., human) PDF or prokaryotic PDF.... Agent: Sloan-kettering Institute For Cancer Research

20120071524 - Compounds for treatment of cancer: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.... Agent:

20120071525 - Anti-microbial composition: The present invention provides an anti-microbial composition comprising (i) an antimicrobial agent with surfactant properties, (ii) a siloxane selected from those having the formulae V:(H3C)[SiO(CH3)2]nSi(CH3)3, and (H3C)[SiO(CH3)HnSi(CH3)3, and mixtures thereof, wherein n is from 1 to 24; and (iii) a polar solvent, wherein the ratio of (i) to (ii) is... Agent: Byotrol PLC

20120071526 - Compounds for the treatment of metabolic disorders: wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R1 is alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from... Agent: Wellstat Therapeutics Corporation

20120071527 - Therapeutic compounds: e

20120071528 - Methods and compositions for treatment of diabetes and dyslipidemia:

20120071529 - Tetrazole compounds which selectively modulate the cb2 receptor:

20120071530 - Agrochemical composition and method for preparing and using the same: An agrochemical composition comprises an azole active ingredient and an N,N-dialkyl long chain alkylamide. The N,N-dialkyl long chain alkylamide is present in sufficient amount to prevent or inhibit the crystallization of the azole derivative during the application of the composition to a locus. Preferred N,N-Dialkyl long chain alkylamide(s) comprised in... Agent: Rotam Agrochem International Co., Ltd.

20120071531 - Use of fungicides for the treatment of fish mycoses: The composition, comprising at least one fungicide selected from the abovementioned group for use in fish farming and keeping is suitable for the prophylaxis and therapy of diseases of fish in aquaculture, in breeding ponds, breeding tanks, aquariums, natural stretches of game fish waters, ponds, and marine fish farms. Addition... Agent: Bayer Cropscience Ag

20120071532 - Novel solid forms of bendamustine hydrochloride: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.... Agent: Cephalon, Inc.

20120071533 - Anti-fungal formulation: Provided herein are compositions and formulations comprising an antifungal agent. Pharmaceutical compositions comprising luliconazole in an amount effective for the treatment of onychomycosis are provided. Also provided are methods for treating dermatomycoses and onychomycosis using the compositions and formulations.... Agent:

20120071534 - Lxr modulators: Compounds, pharmaceutically acceptable salts, isomers, or prodrugs thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.... Agent:

20120071535 - Estrogen receptor modulators and uses thereof: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon... Agent: Aragon Pharmaceuticals, Inc.

20120071536 - N-[(2-azabicyclo[2.1.1]hex-1-yl)-aryl-methyl]-benzamide derivatives, preparation thereof, and therapeutic use thereof: The invention relates to N-[(2-aza-bicyclo[2.2.1]hex-1-yl)-aryl-methyl]-benzamide derivatives of the general formula (I) where: R is a hydrogen atom or a (C1-C6)alkyl group, (C3-C7)-cycloalkyl, optionally substituted by one or more fluorine, (C3-C7)-cycloalkyl, (C2-C4)alkenyl, phenyl, (C1-C6)alkoxy, hydroxy; R1 is phenyl or naphtyl optionally substituted by one or more halogen, (C1-C6)alkyl, (C1-C6)alkoxy, halo-(C1-C6)alkyl, NR4R5,... Agent: Sanofi

20120071537 - New oral formulation: The present invention relates to a pharmaceutical composition, in particular to a composition for administering active agents which are poorly soluble in aqueous media, and/or which are acid sensitive.... Agent:

20120071538 - Pharmaceutical formulatons: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of... Agent: Ferring B.v.

20120071549 - Anti-inflammatory composition containing macrolactin a and a derivative thereof as active ingredients: The present invention relates to an anti-inflammatory use of macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A and 7-O-succinyl macrolactin A, which are produced from a novel Bacillus strain of Bacillus polyfermenticus KJS-2 (KCCM10769P). The macrolactin compounds provided by the present invention were confirmed to greatly suppress the expression... Agent: Daewoo Pharmaceutical Ind. Co., Ltd.

20120071547 - Compounds from soft coral, method of preparation and pharmaceutical uses thereof: The invention relates to compounds from the soft coral and the generation thereof. The invention also relates to the uses of the compounds from the soft coral in inhibiting inducible nitric oxide synthase and/or cyclooxygenase-2 and in treating the diseases associated with inducible nitric oxide synthase and/or cyclooxygenase-2.... Agent: National Sun Yat-sen University

20120071548 - Therapeutic compositions: These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the... Agent: Btg International Limited

20120071550 - Synergistic combinations of cartonoids and polyphenols: The present invention provides a therapeutic composition comprising one or more polyphenols and one or more carotenoids selected from the group consisting of lutein, lycopene and beta-carotene. The invention also provides methods for inhibiting or reducing the production of superoxide ions, NO, TNF-alpha and/or PGE2 in a mammalian subject comprising... Agent: Lycored Ltd.

20120071551 - Ethanolic extracts of hass avocado seeds, persea americana mill., and its use as miticide for panonychus citri, oligonychus yothersi, and tetranychus cinnabarinus, and as an insecticide for trialeurodes vaporariorum: An ethanolic extract of avocado seeds with a composition of 2-Furfuraldehyde (1,00%), 5-Methylundecane (1,05%), (11Z)-Pentadecenal (0,98%), (11Z)-Hexadecenal (2,35%), (3E)-Nonadecene (1,07%), 2-Tetradecylfuran (5,58%), 2-Pentadecylfuran (7,10%), 2-Hexadecylfuran (6,52%), 2-(1Z-Heptadecenyl) furan (2,85%), 2-(1E-Pentadecenyl) furan (2,15%), 2-(1E-Heptadecenyl) furan (5,60%), 2-(8Z, 11Z-Heptadecadienyl) furan (5,49%), 2-(8Z, 11 E-Heptadecadienyl) furan (33,53%), 2-(1 E, 8Z, 11Z-Heptadecatrienyl) furan (15,56%),... Agent:

20120071552 - Zinc-monocysteine complex and method of using zinc-cysteine complexes: A method of providing zinc to a subject in need of treatment includes administering to the subject an effective amount of a zinc-cysteine complex. The zinc-cysteine complex is preferably a zinc-monocysteine complex. The complexes of zinc-cysteine of the present invention increase the activity of antioxidant enzymes catalase and glutathione peroxidase,... Agent:

20120071553 - Chlorine-free water treatment: A combination of the surfactant SDS with levulinic acid produces a synergistic effect in relation to the antimicrobial effectiveness of the individual compounds, allowing the formulation of compositions wherein the active agents are present at concentrations effective to reduce bacterial and fungal counts in liquids, including, but not limited to,... Agent: University Of Georgia Research Foundation, Inc.

20120071557 - Animal feed compositions of abscisic acid: The invention relates to compositions comprising abscisic acid, and/or salts, and derivatives thereof, and methods of using the same for improving the health, growth, and feed efficiency of livestock and fish as well as the quantity of meat produced in livestock in particular.... Agent:

20120071555 - Compositions of abscisic acid for animal health: The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of using the same for improving the health and offspring mortality of animals.... Agent:

20120071554 - Deuterated 2-propylpentanoic acid compounds: Described herein are novel analogs of 2-propylpentanoic acid, pharmaceutical compositions comprising the same, and methods of using the same for the treatment of diseases or conditions that are beneficially treated by administering a GABAAergic transmission enhancer and/or a histone deacetylase (HDAC) inhibitor.... Agent:

20120071556 - Pharmaceutical and nutraceutical compositions of abscisic acid: The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of pharmaceutical and/or nutraceutical use.... Agent:

20120071558 - Compositions of very long chain polyunsaturated fatty acids and methods of use: The present invention relates to processes for production of Very Long Chain Polyunsaturated Fatty Acids (VLC-PUFAs). The present invention also relates to compositions (e.g., nutritional supplements, food products, and pharmaceutic compositions) containing such VLC-PUFAs. In one embodiment, the present invention is directed to methods for biosynthesis and production of the... Agent:

20120071559 - Methods of quantifying n2-(1-carboxyethyl)-2'-deoxy-guanosine (cedg) and synthesis of oligonucleotides containing cedg: Methods of quantifying a N2-carboxyethyl-2′-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of disorders, including diabetes and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG levels before and after treatment. Measurement of CEdG levels... Agent:

20120071560 - Monoamine reuptake inhibitors: The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake... Agent: Research Triangle Institute

20120071561 - Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease and transplant rejection: The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for... Agent:

20120071562 - 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses: This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as... Agent: Wisconsin Alumni Research Foundation

20120071563 - Stabilizer: i

20120071564 - Emulsions based on hydroxyl compounds bearing silyl groups: The invention relates to emulsions containing hydroxyl compound bearing silyl groups, to the production and to the use thereof... Agent: Evonik Goldschmidt Gmbh

20120071565 - Powdery or granulated composition comprising a copolymer, a dicarboxylic acid and a fatty monocarboxylic acid: A powdery or granulated composition, containing: (a) a copolymer containing, in polymerized form, a C1- to C4-alkyl ester of acrylic or methacrylic acid and an alkyl(meth)acrylate monomer containing a tertiary amino group in an alkyl radical; (b) 0.5 to 10% by weight based on (a) of a dicarboxylic acid having... Agent: Evonik Roehm Gmbh

20120071566 - Bioabsorbable polymeric compositions, processing methods, and medical devices therefrom: Novel bioabsorbable polymeric blends are disclosed. The blends have a first component that is a polylactide polymers or a copolymer of lactide and glycolide and a second component that is poly(p-dioxanone) polymer. The novel polymeric blends provide medical devices having dimensional stability. Also disclosed are novel bioabsorbable medical devices made... Agent:

20120071568 - Cosmetic composition: An object of the invention is to provide a cosmetic composition that is not drippy during makeup removal, has good skin spreadability during use, has a refreshing feeling in use, and provides a high cleansing effect, and in particular, to provide a cleansing composition. The cosmetic composition according to the... Agent: Shiseido Company, Ltd.

20120071567 - Fruit flavored cocoa butter based confection: A fruit flavored confection made of a fruit based anhydrous component, along with sweeteners dairy and suitable confectionary fat wherein the intimate incorporation of the fruit based component and the acidic pH of the confection results in a vibrant fruit flavor profile.... Agent:

20120071569 - Process for producing gel of carboxymethyl cellulose alkali metal salt: f

20120071570 - Novel acyl acidic amino acid ester: Provided is a novel oily material that spreads smoothly upon application and is free from stickiness, and also gives ungreasy and moisturized feeling after application, but does not give friction feeling peculiar to silicone. The invention was completed upon finding that a specific acyl acidic amino acid monosilicone monosterol ester... Agent: Ajinomoto Co., Inc.

  
03/15/2012 > 156 patent applications in 112 patent subcategories. listing by industry category

20120065124 - Cell-penetrating peptides: (D) a peptide having: the reverse sequence of any of (A) to (C); an amino acid sequence which is the same as the reverse sequence of (A) except that one or several basic amino acids are changed; or an amino acid sequence which is the same as the reverse sequence... Agent: Toray Industries, Inc.

20120065122 - Pharmaceutical composition and method for modulating slow myosin: The present invention directed to a method for modulating the expression level of slow myosin comprising administering to a subject in need thereof a therapeutically effective amount of nuclear receptor interaction protein (NRIP) modulator and calmodulin, and a pharmaceutically acceptable carrier.... Agent: National Taiwan University

20120065123 - Synthetic antibodies: Methods for synthetic antibodies, methods for making synthetic antibodies, methods for identifying ligands, and related methods and reagents.... Agent:

20120065125 - Methods and compositions for the treatment of cancer or other diseases: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells... Agent: City Of Hope

20120065126 - Pharmaceutical compositions containing antifungal peptides: The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.... Agent: Basf Se

20120065127 - Novel bacillus thuringiensis gene with lepidopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20120065128 - Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8-aminocaprylic acid: The present invention relates to crystalline polymorphic forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, pharmaceutical compositions containing the same, methods of preparing the same, and methods for facilitating the delivery of active agents with the same.... Agent: Emisphere Technologies, Inc.

20120065129 - Method of mass producing growth factor using adipose derived adult stem cells: The present invention relates to a method for producing large amounts of human growth factors from human adipose-derived stem cells. More specifically, the invention provides a method capable of synthesizing human growth factors in significantly large amounts by culturing adipose-derived stem cells extracted from human adipose cells in suitable media... Agent: Prostemics Co., Ltd.

20120065130 - Methods for treating congestive heart failure: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.... Agent:

20120065131 - Compositions and methods for topical application and transdermal delivery of an oligopeptide: The invention relates to the transdermal application of oligopeptides for reducing synaptic transmission in tissues of an animal. In one aspect, this invention relates to compositions comprising an oligopeptide and optionally a carrier comprising a positively charged “backbone” having positively charged branching or “efficiency” groups, as described herein. Most preferably... Agent: Revance Therapeutics, Inc.

20120065132 - Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure: A method of treatment for treating, preventing, inhibiting or reducing tissue deterioration, injury or damage due to congestive heart failure disease, or for restoring tissue adversely affected by said disease, in a subject, includes administering to a subject an effective amount of a composition including a peptide agent including amino... Agent: Regenerx Biopharmaceuticals, Inc.

20120065133 - Artificial oxygen transport protein: This invention provides heme-containing peptides capable of binding molecular oxygen at room temperature. These compounds may be useful in the absorption of molecular oxygen from molecular oxygen-containing atmospheres. Also included in the invention are methods for treating an oxygen transport deficiency in a mammal.... Agent: The Trustees Of The University Of Pennsylvania

20120065134 - Cd40-l inhibitory phylomer peptides: The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signalling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-CD40L... Agent:

20120065135 - Genetically modified tfpi and method of making the same: The present invention provides long half life genetically modified TFPI sequences (LTFPI) for anticoagulation. On the genetically modified TFPI sequence, the lysine at the carboxy-terminal sites 241, 254, 260 and 261 are replaced by alanin and the amino acid asparagine at glycosylation sites 117, 167, 228 and the amino acids... Agent: Fudan University

20120065136 - Recombinant factor viii having enhanced stability following mutation at the a1-c2 domain interface: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having... Agent: University Of Rochester

20120065137 - Therapeutics for trauma induced factor v consumptive coagulopathy: A process of treating trauma induced factor V consumptive coagulopathy is presented whereby a subject is administered a preparation of isolated factor V or a variant thereof. Administration of factor V surprisingly improves clot times and reduces the severity and propensity of bleeding events.... Agent:

20120065138 - Lipids, lipid complexes and use thereof: p

20120065139 - Gq protein competitive inhibitory polypeptides, preparation methods and uses thereof: Provided are a series of Gq protein competitive inhibitory polypeptides (GCIPs), polynucleotides encoding them, and preparation methods thereof. Also provided are pharmaceutical compositions comprising GCIP polypeptides and their uses in the manufacture of drugs for treating myocardial hypertrophy.... Agent:

20120065140 - Biomarkers for the diagnosis of autoimmune disease: Compositions and methods are provided for diagnosis and treatment of rheumatoid arthritis. Defects in T cell receptor signaling lower the activation threshold of RA T cells, thus predisposing for a failure in maintenance of immune tolerance. Overexpression of B-Raf and/or K-Ras in CD4 T cells lowers the threshold to respond... Agent:

20120065143 - Dose and localization of botulinum toxins in skin and muscle: A novel dosing regimen for the administration of botulinum toxin based on the pattern, quantity, and location of neuromuscular junctions in the target tissue. Because the number of neuromuscular junctions in a target tissue remains generally stable throughout life and because the pharmacological effect of botulinum toxin is localized at... Agent: Dt Scimed, LLC

20120065142 - Novel solid materials of and methods for obtaining them: The instant invention relates to novel solid materials of {[(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid}, methods for producing them, and the use of said solid materials in pharmaceuticals.... Agent: Merck Patent Gmbh

20120065141 - Stabilized biodegradable neurotoxin implants: Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in... Agent: Allergan, Inc.

20120065144 - Peptide for the prophylactic or therapeutic treatment of skin tumors in initial stages: It comprises an inhibitor peptide of TGF-β1 for use in preventive or therapeutic treatment of skin tumors at early stages, in which the peptide is disitertide or a derivate thereof, and a pharmaceutical composition that comprises a therapeutically effective amount of the peptide.... Agent: Isdin, S.a.

20120065145 - Alkylating agent combinations in the treatment of cancer: This application provides compositions and methods useful in the treatment of certain cancers. In part, this application is based on the recognition that certain molecules that target abasic lesions or AP sites in DNA improve, augment, or potentiate the chemotherapeutic efficacy of certain anticancer agents.... Agent:

20120065146 - Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use: Found in various eukaryotic organisms, polo-like kinases (collectively, Plks) are a conserved subfamily of Ser/Thr protein kinases that play critical roles in cell proliferation. Provided herein are compounds that specifically inhibit the activity of Plks, specifically Plk1. Further provided herein are methods for use of the compounds for the treatment... Agent: Government Of The United States Of America, As Represented By The Secretary, Department Of Health

20120065147 - Use of the gtpase rab27b to diagnose and treat poor prognosis estrogen-receptor-positive breast cancer: The present invention relates to evaluating the prognosis of patients with estrogen receptor-positive breast cancer on the basis of Rab27B expression. The invention further relates to a kit comprising an assay for measuring Rab27B levels in said patients and to the usage of Rab27B as a target to screen for... Agent:

20120065148 - Phosphodiesterase 4d7 as prostate cancer marker: The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for prostate cancer, and the use of PDE4D7 as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring... Agent: Koninklijke Philips Electronics N.v.

20120065149 - Vitamin receptor binding drug delivery conjugates: The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes... Agent:

20120065150 - Neuroprotective effects of 2dg in traumatic brain injury: This invention provides methods for reducing the extent and progression of traumatic brain injury and its deleterious sequellae specifically cognitive decline, post-traumatic epilepsy, post-traumatic stress disorder, and other adverse consequences depending on the progression of the initial injury, comprising administering to a TBI victim in need thereof a therapeutically-effective amount... Agent: Wisconsin Alumni Research Foundation

20120065151 - Substances mixture, use and infusion solution: The present disclosure relates to a substance mixture, wherein the substance mixture contains ribose, alanine, nicotinic acid and ascorbic acid.... Agent:

20120065152 - Prodrugs of guanfacine: Prodrugs of guanfacine, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for improving the pharmacokinetics of guanfacine or minimizing or avoiding the adverse gastrointestinal side... Agent: Shire LLC

20120065153 - Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof: The invention concerns heparanase inhibiting compounds of general formula (I) wherein R represents a hydrogen atom, an hydroxyl radical, a —OSO3— radical, a —O—(C1-C5)alkyl radical or an —O— aralkyl radical; Z represents a COO− radical or a hydroxyl radical; X represents —OH or a saccharide unit of formula A, Y... Agent: Sanofi-aventis

20120065154 - Pyrazolo pyrimidine derivatives and methods of use thereof: This invention generally relates to pyrazolo pyrimidine derivatives useful as, inter alia, inhibitors of short chain dehydrogenase/reductase (SDR) family of NAD(P)(H) dependent oxido-reductases. More specifically, the invention relates to pyrazolo pyrimidine derivatives, including derivatives and analogs of SDR inhibitors, pharmaceutical compositions containing derivatives and analogs of SDR inhibitors, methods of... Agent: The Regents Of The University Of California

20120065249 - Antisense oligonucleotides for treating allergy and neoplastic cell proliferation: Antisense oligonucleotides for treating and/or preventing at least one of asthma, allergy, hypereosinophilia, general inflammation and cancer are provided. The oligonucleotides are directed against nucleic acid sequences coding for a receptor selected from the group consisting of a CCR3 receptor and a common sub-unit of IL-3, IL-5 and GM-CSF receptors.... Agent: Topigen Pharmaceuticals Inc.

20120065248 - Methods and compositions involving mirna and mirna inhibitor molecules: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors... Agent:

20120065247 - Modulating ires-mediated translation: Provided herein are compounds and methods for use in preventing or treating a viral infection mediated by a virus comprising an IRES-containing RNA molecule or cancer related to an increase or decrease in IRES-mediated translation of an RNA molecule. Also provided are methods of inhibiting or promoting IRES-mediated translation. Also... Agent: The Uab Research Foundation

20120065244 - Oligomers: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce... Agent: Royal Holloway And Bedford New College, University Of London

20120065242 - Polymeric nano-particles for sirna delivery using charge interaction and covalent bonding: The polymer-siRNA delivery carrier in which a polymer and a siRNA are combined by using charge interaction and biodegradable covalent bonding at the same time has a high siRNA deliver efficiency to a target portion in vivo. Hence, according to the polymer-siRNA binder, the siRNA for treatment can be effectively... Agent:

20120065245 - Regulation of hematopoietic stem cell functions through micrornas: The present disclosure relates to regulation of functions of hematopoietic stem cells (HSCs) by delivering of miRNAs, including miR-125b, miR-126, and miR-155, to HSCs. For example, in some embodiments, blood output in a mammal can be increased by administering miR-125b, miR-126, and/or miR-155 oligonucleotides. Also disclosed are methods for promoting... Agent: California Institute Of Technology

20120065243 - Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality: The present invention relates to RNAi constructs and their use in gene silencing. RNAi constructs associated with the invention contain a double stranded region connected to a single stranded region of phosphorothioate modified nucleotides.... Agent: Rxi Pharmaceuticals Corporation

20120065246 - Rna molecules and therapeutic uses thereof: The invention relates to double-stranded RNA molecules in which each strand of said molecule possesses: (a) sufficient complementarity to a target mRNA molecule to facilitate cleavage thereof; and (b) sufficient complementarity to the other strand of the double-stranded RNA molecule so as to form a stable duplex; and in which... Agent: Mina Therapeutics Limited

20120065250 - Sirna targeting apolipoprotein b (apob): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Dharmacon, Inc.

20120065254 - C5a binding nucleic acids and the use thereof: The present invention is related to a nucleic acid molecule, capable of binding to C5a, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of tumors, the treatment and/or prevention of a respiratory disease, the treatment and/or prevention of pain and/or the treatment... Agent: Noxxon Pharma Ag

20120065252 - Engineered nucleic acids and methods of use thereof: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject's heath or wellbeing.... Agent:

20120065253 - Genetic modification of targeted regions of the cardiac conduction system: Disclosed are methods and systems for preventing or treating cardiac dysfunction, particularly cardiac pacing dysfunction by genetic modification of the conduction system of the heart. In one embodiment, the invention provides a method of genetically modifying the cells by delivering to the cells one or more coding sequence in a... Agent: Medtronic, Inc.

20120065251 - Mir-21 promoter driven targeted cancer therapy: The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.... Agent:

20120065155 - A3 adenoside receptor agonists for the reduction of intraocular pressure: The present disclosure provides the use of an A3R agonist, such as IB-MECA, for reducing in a subject, preferably, human subject, intra ocular pressure (IOP). Similarly, the invention provides a pharmaceutical composition and a method for reducing IOP in a subject making use of the A3R agonist.... Agent: Can-fite Biopharma Ltd.

20120065156 - Uracyl spirooxetane nucleosides: e

20120065159 - Composition containing chamaecyparis obtusa polysaccharides to be externally applied to the skin: The present invention relates to a composition for skin external application containing a Chamaecyparis obtusa polysaccharide as an active ingredient, and more particularly to a composition for skin external application containing a Chamaecyparis obtusa polysaccharide, which improves skin elasticity and reduces wrinkles by promoting collagen production, shows an excellent skin-whitening... Agent: Amorepacific Corpoation

20120065158 - Fucoidan having antitumor activity: Disclosed is a medium-molecular weight fucoidan which can be used in treating and/or preventing proliferative diseases, in particular, cancer. Specifically disclosed are a medium-molecular weight fucoidan, a method for producing the same, a medicinal composition containing the same, and use of the medium-molecular weight fucoidan in producing a drug for... Agent:

20120065157 - Particulate-soluble glucan preparation: Particulate β-glucan is solubilized at elevated pressure and temperature to form particulate-soluble β-glucan. The particulate-soluble β-glucan is capable of being dried to a powder form and subsequently re-solubilized.... Agent:

20120065160 - Delivery system for delivery of a substance into the oral cavity: A delivery system for use in the oral cavity, the system comprising a carrier for a bioactive substance. The carrier has a surface comprising oxygen-binding sites (X), and at least one link comprising a pentose group and one or more additional sugar groups, the pentose group being bonded to one... Agent: Neoinvent Medical Engineering Ab

20120065161 - Cyclodextrin-based polymers for therapeutic delivery: Methods and compositions relating to CDP-epothilone conjugates are described herein.... Agent: Cerulean Pharma Inc.

20120065164 - Fungicide pyrazole carboxamides derivates: The present invention relates to pyrazole carboxamides derivatives of formula (1) wherein Y represents CR5 or N, T represents S or O, X1 and X2 represent a chlorine or a fluorine atom, and Z1 represents a substituted or non-substituted cyclopropyl; Their process of preparation, their use as fungicide, and/or anti-mycotoxin... Agent:

20120065162 - N-n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors: or a salt thereof, wherein R101 and R102 are each independently a phenyl group or a pyridyl group, the phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine... Agent: Otsuka Pharmaceutical Co., Ltd.

20120065163 - Sebum absorption compositions: Sebum absorption compositions are disclosed which include (a) 1% to 20% by weight of the composition of a sebum absorption ingredient; and (b) 20% to 99% by weight of the composition of a volatile solvent.... Agent: Mary Kay Inc.

20120065165 - Compositions and methods of treating endothelial disorders: Compositions and methods of treating endothelial disorders, including: asthma, erectile dysfunction, pulmonary hypertension, cardiovascular disorders, and other disorders, using a synergistic combination of at least one arginase inhibitor and at least one phosphodiesterase (PDE1), (PDE2) and/or (PDE5) inhibitor are described.... Agent: Arginetix, Inc

20120065166 - Bone modulators and methods therewith: THE INVENTION RELATES TO compositions, compounds, proteins and methods of treatment therewith. Aspects of embodiments also relate to a method of treating a patient by delivering to the tissues of said patient or administering to said patient a therapeutically effective amount of one or more compounds. Aspects of embodiments also... Agent:

20120065167 - Domperidone at a low daily dose for use in the treatment or prevention of a disease associated with an alteration of the immune response: The invention relates to the use of domperidone or a pharmaceutically acceptable salt thereof at low doses to prevent and/or treat a disease associated with an alteration of the immune response such as Leishmaniosis.... Agent: Laboratorios Del Dr. Esteve S.a.

20120065168 - Pharmaceutical hypocholesterolemic compositions: The present invention relates to novel azetidinone-containing compounds having a novel side-chain which is attached to the aryl ring at C4 via a C—C bond and comprises a 3,3-disubstituted oxetane ring and a polar group A, and which are useful in the treatment and prevention of atherosclerosis and for the... Agent: Lipideon Biotechnology Ag

20120065169 - Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups: Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.... Agent:

20120065170 - Antimicrobial cyclocarbonyl heterocyclic compounds for treatment of bacterial infections: i

20120065171 - Fostriecin derivatives and the pharmaceutical uses thereof: Novel Fostriecin (or FST) derivatives represented by formula (I), the pharmaceutical compositions and preparation methods thereof. The pharmaceutical uses of these compounds, especially the use for the preparation of pharmaceutical compositions for treating tumor, inhibiting cell over growth, or lowering myocardial infarction and the injury to cells.... Agent: Baygen Pharm Technology Co., Ltd.

20120065172 - Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications: A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.... Agent:

20120065173 - Chemical compounds: p

20120065174 - Compositions of glycopyrronium salt for inhalation: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.... Agent:

20120065175 - Method of preparing dry powder inhalation compositions: The invention provides a method of preparing a dry powder inhalation composition comprising a pharmaceutically acceptable particulate carrier, a first particulate inhalant medicament and a second particulate inhalant medicament. Also provided are dry powder compositions and methods of using them with a dry powder inhalation device.... Agent: Norton Healthcare Limited

20120065176 - Treatment of muscle disease characterized by insulin resistance: It is reported herein that certain muscle diseases and conditions, including forms of muscular dystrophy, are characterized by impaired insulin-dependent signaling in the muscle tissue, in essence, a form of insulin resistance. The present disclosure relates to therapeutic agents, compositions and methods for treating a muscle disease or condition characterized... Agent:

20120065178 - Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present... Agent: Allergan, Inc.

20120065177 - Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions: h

20120065180 - Androgen pharmaceutical composition and method for treating depression: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a... Agent:

20120065179 - Prodrug comprising beta-keto carboxylic acid, beta-keto carboxylic acid salt or beta-keto carboxylic acid ester for drug delivery: There is provided a prodrug of a pharmaceutically active agent, such prodrug comprising a beta-keto carboxylic acid, a beta-keto carboxylic acid salt or a beta-keto carboxylic acid ester functional group, a pharmaceutical composition comprising the prodrug, and to the use of the prodrug or composition for treatment of a mammalian... Agent: Yki, Ytemiska Institutet Ab

20120065181 - Method of providing neuroprotection using substituted porphyrins: Described herein are methods of treating ischemic injury comprising administering to a subject in need thereof a therapeutically effective amount of a substituted porphyrin compound. Also disclosed are methods of providing neuroprotection, methods of treating subarachnoid hemorrhage, methods of treating traumatic brain injury and methods of treating spinal cord injury... Agent:

20120065182 - Stabilizing compositions for antibiotics and methods of use: The present invention is directed to improved liquid antibiotic formulations. In some embodiments, the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).... Agent: Taro Pharmaceuticals North America, Inc.

20120065184 - Compounds and compositions as trk inhibitors: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.... Agent: Irm LLC

20120065185 - Substituted alkylamine derivatives and methods of use: Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.... Agent: Amgen Inc.

20120065183 - Tetrahydro-pyrido-pyrimidine derivatives: l

20120065186 - Antimicrobial compositions: The present invention relates to antimicrobial compositions and more specifically compositions of quinolone carboxylic acid derivatives. These compositions have improved solubility, stability, and tolerability. These compositions are useful for intravenous administration for treating, preventing, or reducing the risk of infection.... Agent:

20120065187 - Heterocyclic inhibitors of histamine receptors for the treatment of disease: The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.... Agent: Kalypsys, Inc.

20120065188 - Substituted heterocyclic derivatives and their pharmaceutical use and compositions: Compounds of the general Formula I, wherein X1, X2, X3, X4, X5, X6, X7, R1, R2, R4, R5, R6, R7, R8, R9, R10, Y1, n, m, p and q are defined as above, their preparation and their use as antimicrobial agents.... Agent: Pfizer Inc

20120065189 - Heterocyclic compounds for the treatment of stress-related conditions: The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R1 and R2, each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene... Agent:

20120065190 - Benzazepine compounds as cgrp receptor antagonists: (wherein variables A1, m, R1, R2, R3, R4 and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these... Agent:

20120065191 - Pharmaceutical compounds: The invention relates to compounds and compositions for inhibiting the enzyme fatty acid amide hydrolase (FAAH), the use of the compounds in therapy and, in particular, for treating or preventing conditions whose development or symptoms are linked to substrates of the FAAH enzyme, and methods of treatment or prevention using... Agent: Bial - Portela & C&#xc2 &#xaa , S.a.

20120065193 - Cyclopropyl amide derivatives '978: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.... Agent:

20120065192 - N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as mps1 kinase inhibitors: The present invention relates to substituted pyrrolyl-pyrimidines which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular MPS1. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases... Agent: Nerviano Medical Sciences S.r.l.

20120065194 - Use of cyproheptadine to treat organophosphate exposure: A method of treating exposure to an organophosphate compound by administering a cyproheptadine compound to a subject in need thereof.... Agent:

20120065195 - Compounds for treating neurodegenerative diseases: The invention provides novel spirotetrahydronaphthalene compounds of Formula α that inhibit β-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.... Agent:

20120065196 - Amide compounds: e

20120065197 - Pyridinylcarboxylic acid derivatives as fungicides: in which the symbols A, X, Y1, Y2, Y3, L1, L2, RG, and R1 are each as defined in the description, and also salts, metal complexes and N-oxides of the compounds of the formula (I), and the use thereof for controlling phytopathogenic harmful fungi and processes for preparing compounds of... Agent: Bayer Cropscience Ag

20120065198 - Detection and treatment of schizophrenia: The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia... Agent: Medical & Biological Laboratories Co., Ltd.

20120065199 - Substituted quinolines for use as vegf inhibitors: e

20120065201 - Inhibitors of bruton's tyrosine kinase: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.... Agent: Pharmacyclics, Inc.

20120065200 - Inhibitors of notum pectinacetylesterase and methods of their use: s

20120065202 - Pyrimidine derivatives as mtor inhibitors: wherein X, R1, R2, T, m, n, o have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation... Agent:

20120065203 - Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids: Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds useful in the treatment of angiogenesis, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus. Also... Agent: The Institute For Pharmaceutical Discovery, LLC

20120065204 - Novel n-hydroxy-benzamids for the treatment of cancer: or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1 to R3 and X have the significances given herein. The present invention is also directed to processes for making said compounds and uses of said compounds, in particular their use as medicaments, more particularly their use as medicaments in... Agent:

20120065205 - Pyrazine carboxamide orexin receptor antagonists: The present invention is directed to pyrazine carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent:

20120065206 - Compounds for treating proliferative disorders: The present invention is directed to compounds represented by structural formula (I), or a pharmaceutically acceptable salt or a transition metal chelate, coordinate or complex thereof or a transition metal chelate, coordinate or complex of a deprotonated form of the compound. Pharmaceutical composition and method of use for these compounds... Agent: Synta Pharmaceuticals Corp.

20120065207 - Methods for concomitant treatment of theophylline and febuxostat: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments... Agent: Takeda Pharmaceuticals North America, Inc.

20120065208 - Cancer treatment: e

20120065211 - Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors: The present invention is directed to alkoxy tetrahydro-pyridopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or... Agent:

20120065210 - Substituted hexahydropyrrolo[1,2-c]imidazolones: e

20120065209 - Tetrahydro-imidazo[1,5-a]pyrazine derivatives salts, preparation methods and medicinal use thereof: Pharmaceutically acceptable salts of (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-formic acid, their preparation methods, compositions containing the said pharmaceutical salts and their use as medicaments, especially as dipeptidyl peptidase IV (DPP-IV) inhibitors are disclosed.... Agent: Jiangsu Hengrui Medicine Co., Ltd.

20120065212 - Heteroarylmethyl amides: wherein A1, A2, A3 and R1 to R8 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis... Agent:

20120065213 - C-met protein kinase inhibitors: Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.... Agent: Vertex Pharmaceuticals Incorporated

20120065214 - Compounds and their uses 708: s

20120065215 - Methods for concomitant treatment of theophylline and febuxostat: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments... Agent: Takeda Pharmaceuticals North America, Inc.

20120065216 - Quinazolinedione derivatives as parp inhibitors: e

20120065217 - Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof: Phycotoxins are purified from a mixture of phycotoxins produced in a continuous process. Cyanobacteria are produced in a continuous culture, then lyzed, the cells pelleted and extracted, and the extract purified using an organic solvent-aqueous mixture and repeated passage through a diatomaceous earth column. The column is washed with acetic... Agent: Proteus S.a.

20120065218 - Heterocyclic cyclopamine analogs and methods of use thereof: The present invention relates to steroidal alkaloids that can be used in the treatment of hedgehog pathway related disorders, particularly cancer.... Agent:

20120065219 - Spirocyclic azaadamantane derivatives and methods of use: The invention relates to compounds that are spirocyclic azaadamantane derivatives, particularly spirocyclic azaadamantanyl ether or amine derivatives, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.... Agent: Abbott Laboratories

20120065220 - Tamper resistant dosage form comprising an anionic polymer: e

20120065221 - Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use: The present invention is directed to oral, therapeutically effective extended release pharmaceutical compositions of 3-hydroxy-N-methylmorphinan, including delayed onset, extended release dosage forms and the use thereof.... Agent: Theraquest Biosciences, Inc.

20120065222 - Devices and methods for reducing scar tissue formation: Disclosed is a cytostatic drug attached to a sterile sheet that is designed to be placed between internal body tissues to prevent the formation of post-operative adhesions, which adhesions are really scar tissue formation. This sheet onto or into which the drug is placed may be either a permanent implant... Agent:

20120065223 - Solid forms of a chemokine receptor antagonist and methods of use thereof: The citrate salt of (S)-4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-ol, which may be used in pharmaceutical applications, is disclosed. The crystalline Citrate Salt, including particular single crystal forms and combinations of the single crystalline forms, are also discussed. Mixtures for forming the crystalline salts are discussed. As well, methods of producing the Citrate Salt, and... Agent:

20120065225 - Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof: e

20120065224 - Pyrrolo[3,2-c) pyridine derivatives and processes for the preparation thereof: The present invention provides novel pyrrolo[3,2-c]pyridine derivatives or pharmaceutically acceptable salts thereof, processes for the preparation thereof, and compositions comprising the same. The pyrrolo[3,2-c]pyridine derivatives or pharmaceutically acceptable salts thereof of the present invention have excellent proton pump inhibition effects and possess the ability to attain a reversible proton pump... Agent: Yuhan Corporation

20120065226 - Salts of tiotropium with 10-camphorsulfonic acid: The present invention relates to novel tiotropium salts with 10-camphorsulphonic acid of formula (I), its optical isomers or their mixtures, their monohydrates, their anhydrous crystalline forms and processes for the preparation thereof, as well as to pharmaceutical compositions containing the same and to the use of novel salts for the... Agent: Adamed Sp Z O.o.

20120065227 - Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors: e

20120065228 - Compositions and methods for treating, controlling, reducing, or ameliorating ocular inflammatory with lower risk of increased intraocular pressure: A composition for treating, controlling, reducing, or ameliorating inflammatory pain comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an additional anti-inflammatory agent and can be formulated for topical application, injection, or implantation. It... Agent:

20120065229 - Insect repellent composition: c

20120065230 - Nitroxide free radical synergized antineoplastic agents: Nitroxide free radicals attached to antineoplastic agents can synergize their potencies to cancer cells. This invention relates to any antineoplastic agents and their derivatives chemically attached with nitroxide free radicals, such as TEMPO and its radical derivatives. This invention also relates to precursors of such compounds, as well as the... Agent: The Trustees Of California State University

20120065231 - Thiophene derivative: The present invention provides a compound represented by the formula (I) or its salt, solvate, or physiologically functional derivative; and a pharmaceutical composition which is useful for treatment or prevention of conditions or disorders having sensitivity to selective androgen receptor modulation, the composition comprising the above-described compound; among others:... Agent: Sumitomo Chemical Company Ltd.

20120065232 - Photostabilization of retinoids with alkoxycrylene compounds: wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, preferably C1-C8, more preferably methoxy, and the non-alkoxy radical R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C30 alkyl radical, preferably C2-C20. The alkoxycrylene compounds of formula (I) significantly increase... Agent: Hallstar Innovations Corp.

20120065233 - Tyrosine kinase inhibitors: The present disclosure relates to the field of tyrosine kinase enzyme inhibition, in particular anaplastic lymphoma kinase (ALK) inhibition using novel small molecules. Provided are compounds capable to modulate ALK activity, compositions that comprise the compounds, and methods of using the compounds for the treatment or prevention of diseases or... Agent:

20120065234 - Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof: wherein R, R1, R2, R3 and R4 are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the... Agent: Sanofi

20120065235 - Compounds for treating proliferative disorders: Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.... Agent: Synta Pharmaceuticals Corp.

20120065236 - Methods for concomitant treatment of theophylline and febuxostat: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments... Agent: Takeda Pharmaceuticals North America, Inc.

20120065237 - Methods for treating transthyretin amyloid diseases: Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed.... Agent: The Scripps Research Institute

20120065238 - Allantoin-containing skin cream: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The composition is in the form of an oil-in-water emulsion. The pH of the composition is in a range of from about 3.0 to about... Agent: Alwyn Company, Inc.

20120065239 - Process for the production of amides:

20120065240 - Method for treating nervous system disorders and conditions: The present invention is directed to selective dopamine reuptake inhibitors, including (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (−)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS), chronic pain, and Shy Drager syndrome.... Agent:

20120065241 - Therapeutic compounds for diseases and disorders: Pyrrole derivatives are disclosed as agents for the treatment and prevention of neuropathies and neurodegenerative diseases characterized by the presence of axonal blockages, impaired axonal transport or impaired trafficking of vesicles in neurons.... Agent: Myrexis, Inc.

20120065255 - Cabazitaxel formulations and methods of preparing thereof: Pharmaceutical formulations comprising cabazitaxel, solubilizer, tocopherol polyethylene glycol succinate (TPGS), one or more hydrotropes, optionally one or more agents having a pKa of about 3 to about 6, and optionally one or more antioxidizing agents, wherein the formulations are substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may... Agent:

20120065256 - Milbemycin compounds and treatment of dermatological disorders in humans therewith: Compounds of the milbemycin family or derivatives thereof are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea.... Agent: Galderma S.a.

20120065257 - Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine: The present invention is a method for the treatment or prevention of migraine comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to a... Agent:

20120065258 - Stable prostaglandin-containing compositions: A pharmaceutical composition containing a prostaglandin and an alkanoic acid ester of a polyethoxylated sorbitol in an amount effective to enhance the chemical stability of the prostaglandin, and the use thereof for treating ophthalmic conditions. Also disclosed are methods for enhancing the chemical stability of a prostaglandin-containing composition by using... Agent:

20120065259 - Heat assisted lidocaine and tetracaine for transdermal analgesia: The present disclosure is drawn to methods for treating various types of pain, including pain associated nerve entrapment, neuroma, headaches, connective tissue, arthritis, injury, and/or overuse. Specifically, the method includes the application of an analgesic system to a skin surface of a subject experiencing the pain and maintaining the analgesic... Agent:

20120065260 - Novel compounds: e

20120065261 - Creatine compositions for skin treatment: The present invention relates to the use of creatine compounds, such as, for example, creatine monohydrate, creatine pyruvate and creatine ascorbate, for the treatment of skin.... Agent: Avicena Group, Inc.

20120065262 - Composition for preventing hair loss or for stimulating hair growth: Provided is a composition for preventing hair loss or promoting hair growth including valproic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The composition may be applied to various industrial fields, including pharmaceutical, cosmetic and beauty aid industries.... Agent:

20120065263 - Retrovirus-infection inhibitor: An infection inhibitor of retrovirus, particularly human immunodeficiency virus, comprising, as an active ingredient, at least one compound selected from the group consisting of a compound represented by the formula (I) (GGA) or a salt thereof, a compound represented by the formula (II) (NIK-333) or a salt thereof, and derivatives... Agent:

20120065264 - Self-emulsifying composition of w3 fatty acid: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance... Agent:

20120065265 - Alpha-2-delta ligands for non-restorative sleep: The use of an alpha-2-delta ligand or a pharmaceutically acceptable salt thereof for the treatment of non-restorative sleep is disclosed.... Agent: Pfizer Inc.

20120065266 - Oral composition: e

20120065267 - Compositions including 3,5-l-t2 and methods of use thereof: Compositions containing 3,5-L-T2 ((2S)-2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid) and methods for use thereof. Among other functions presented herein, 3,5-L-T2 can lower cholesterol via a mechanism that is independent of LDL receptor function. Disclosed compositions may include one or more additional active agents, such as, but not limited to, thyroid hormones other than 3,5-L-T2,... Agent: T*amine, LLC

20120065268 - High concentration baclofen preparations: Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions.... Agent: Board Of Regents, The University Of Texas System

20120065269 - System for reducing bacteria on unprocessed food surfaces while extending shelf life: A system for substantially reducing surface contaminants of a food substance comprising a substantially transparent and odorless solution made from a plurality of substantially organic compounds selected from: citric acid, sodium citrate, vegetable glycerin, sea salt, potassium sorbate, decyl glucoside, calcium ascorbate, grapefruit seed extract, and sodium bisulfite, and an... Agent:

20120065270 - Potassium ion channel modulators and uses thereof: s

20120065271 - Method of accelerating muscle growth, decreasing fat deposits and improving feed efficiency in livestock animals: A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of... Agent:

20120065272 - Novel use of panduratin derivatives or extract of kaempferia pandurata comprising the same: The present invention relates to a new use of panduratin derivatives or a Kaempferia pandurata extract comprising the same. More particularly, the present invention relates to a composition for improving wrinkles and/or preventing aging, which comprises a panduratin derivative or a Kaempferia pandurata extract comprising the same. The said the... Agent: Newtree Co., Ltd.

20120065273 - Tto-based wide spectrum therapeutics, disinfectants & anesthetics for use in aquaculture: The invention discloses a novel wide spectrum aquaculture pharmaceutical, comprising a therapeutic, disinfective and/or anesthetize effective amount of a preparation comprising TTO in a stable water-in-oil emulsion of alkali or ammonium salts of organic fatty acid; said emulsion is also stable when converted into an oil-in-water emulsion, wherein the preparation... Agent: Biomor Israel Ltd.

20120065274 - Azeotrope-like compositions comprising 1-chloro-3,3,3-trifluoropropene: An azeotrope-like mixture consisting essentially of chlorotrifluoropropene and at least one component selected from the group consisting of a C1-C3 alcohol, a C5-C6 hydrocarbon, a halogenated hydrocarbon, methylal, methyl acetone, water, nitromethane, and combinations thereof.... Agent: Honeywell International Inc.

20120065275 - Polysaccharide compositions: An aqueous composition characterized in that it comprises one or more anionic polysaccharides suspended in an aqueous dispersion of one or more hydrocolloids.... Agent: Cargill Incorporated

20120065276 - Rinse-off personal care compositions: The present invention relates to a cleanser composition comprising a) from about 1% to about 20% of fatty acid soap containing from about 8 to about 16 carbon atoms; b) from about 2% to about 20% of a synthetic surfactant; and c) water, wherein the composition comprises a metal ion... Agent:

20120065277 - Microfluidic chemostat: A chemostat is described that includes a growth chamber having a plurality of compartments. Each of the compartments may be fluidly isolated from the rest of the growth chamber by one or more actuatable valves. The chemostat may also include a nutrient supply-line to supply growth medium to the growth... Agent: California Institute Of Technology

  
03/08/2012 > 141 patent applications in 112 patent subcategories. listing by industry category

20120058932 - Active ingredient-peptide construct for extracellular concentration: The present invention relates to an active ingredient-peptide construct for extracellular concentration, a process for the concentration of active ingredients in an extracellular space of a multicellular object, the use of the active ingredient-peptide construct according to the invention for the production of a medicinal product and a pharmaceutical composition... Agent: Max Planck-gesellschaft Zur Forderung Der Wissenschaften E.v.

20120058931 - Drug target that promotes secretory granule-granule fusion: Munc18 proteins facilitate formation of SNARE complexes known to mediate membrane fusion. Much is known about the fusion of secretory granule (SG) to plasma membrane, mediated by Munc18a-SNARE complexes. It has been found that another Munc18 isoform, Munc18b, mediates SG-SG fusion which causes potentiation of secretion. The present invention has... Agent:

20120058933 - Synthetic peptides and peptide mimetics: The present invention provides Parotid Secretory Protein peptides, nucleic acids encoding the peptides, and methods of using the peptides, and methods of screening GL13 mimetics.... Agent: University Of Louisville Research Foundation

20120058934 - Treatment of diseases: e

20120058935 - Antimicrobial compositions and methods of use therefore: The invention features antimicrobial compositions comprising β-amyloid peptides, oligomers, and analogs thereof, and methods of using them for the prevention or treatment of an infection.... Agent: The General Hospital Corporation

20120058936 - Compositions and methods for elimination of gram negative bacteria: Oral drug delivery formulations which specifically administer antibacterial agents to the ileum, caecum, and/or the colon, without significant administration elsewhere in the gastrointestinal tract, are disclosed. The formulations include, as actives, a combination of a macrolide or aminoglysoside, or quinolone antibacterial and an anti-Gram-negative lipopeptide (polymyxin) antibacterial agent or other... Agent: Universite Paris Diderot - Paris 7

20120058937 - Prodrugs of neuraminidase inhibitors: A new class of neuramidase inhibitor prodrugs is provided characterized by a prodrug moiety of a carboxyl group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide or a carbonyl ethoxy tripeptide, a guanidine group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide,... Agent: Tsrl, Inc.

20120058938 - Nutritional composition inducing a postprandial endocrine response: The invention concerns the use of a nutritional composition for the treatment of disorders which are associated with malfunctioning in the uptake and use of food-derived energy in the human body. In particular, the invention concerns the use of a nutritional composition for the treatment of a disorder, which is... Agent: N.v. Nutricia

20120058939 - Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof: Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.... Agent: Albany Molecular Research, Inc.

20120058940 - Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof: Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.... Agent: Albany Molecular Research, Inc.

20120058941 - Glucopyranoside compound: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene... Agent:

20120058942 - Methods for controlling blood-glucose levels in insulin-requiring subjects: The present invention relates to methods of controlling blood glucose levels in subjects receiving an insulin therapy. The methods include administering to the subject receiving an insulin therapy a dipeptidyl peptidase inhibitor and a GLP-1 related peptide. The present invention relates also to the use of such a combination for... Agent:

20120058943 - Bioactive hydrogel: The invention relates to a bioactive hydrogel as a hybrid material of heparin and star-branched polyethylene glycol with functionalized end groups, wherein the heparin is bound directly by reaction of the carboxyl groups activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimides/N-hydroxysulfosuccinimide (EDC/s-NHS) with the terminal amino groups of the polyethylene glycol covalently by amide... Agent: Zetascience Gmbh

20120058944 - Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity: The present invention is directed to an isolated peptide comprising or consisting of an amino acid sequence with an amino acid identity of at least 90% compared to mature human BMP2 with SEQ ID No. 1, characterized in that said amino acid sequence comprises at least two amino acid substitutions... Agent:

20120058945 - Neuroprotective iron chelators and pharmaceutical compositions comprising them: Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, e.g., a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, an inflammatory disorder,... Agent: Technion Research And Development Foundation Ltd.

20120058946 - Compound and method for treating myotonic dystrophy: An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary... Agent: Avi Biopharma, Inc.

20120058947 - Prophylactic agent for heart failure: The present invention provides an agent having a suppressive action against the thickening of the heart wall, a prophylactic agent for heart failure containing the above described agent, and functional foods expected to have a prophylactic effect for heart failure. The agent for suppressing heart wall thickening comprises Xaa Pro... Agent:

20120058948 - Collagen peptides as immune modulators: The invention relates to collagen peptides, as well as related methods. The invention also relates to methods and products for modulating cytokine production and/or inflammation.... Agent:

20120058949 - Methods of treating neurological disorders: The present invention provides methods of treating epilepsy and other neurological disorders. The methods generally involve administering to an individual in need thereof an effective amount of an agent that blocks a transforming growth factor-beta pathway.... Agent:

20120058950 - Detection of neuropeptides associated with pelvic pain disorders and uses thereof: Diagnostic assessment and therapeutic treatment of pelvic pain disorders, including bladder disorders, bowel disorders, and/or reproductive tissue or organ disorders that are characterized by increased expression of the neuropeptides CGRP and/or PACAP. Additionally, applicants have developed a transgenic non-human model for pelvic pain disorders, where the transgenic animal expresses in... Agent: University Of Rochester

20120058951 - Neurotensin receptor agonists and opioid receptor agonists: This document provides methods and materials for treating pain. For example, this document provides methods that involve administering a neurotensin receptor (NTR) agonist and an opioid receptor agonist to a mammal (e.g., a human). Compositions containing an NTR agonist in combination with an opioid receptor agonist also are provided.... Agent:

20120058952 - Hmg-coa reductase derived peptide and cosmetic or pharmaceutical composition containing same: The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to... Agent: Isp Investments Inc.

20120058953 - Compositions and methods for enhancing apoptosis: The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20120058954 - Diaza heterocyclic compounds for phototherapy: The invention relates generally to optical agents, including phototherapeutic agents, for biomedical applications, including phototherapy. The invention includes optical agents, and related therapeutic methods, comprising alicyclic diaza compounds, including 1,2 diaza heterocyclic compounds, having a photolabile N—N bond directly or indirectly linked to at least one carbocyclic aromatic and/or heterocyclic... Agent:

20120058955 - Use of decorine for increasing muscle mass: The invention concerns decorin for increasing muscle mass, particularly in the treatment of muscular dystrophies.... Agent: Association Francaise Contre Les Myopathies

20120058956 - Peptides derived from ficolin as surfactants: Provided are peptides having a sequence that is a subsequence of a ficolin protein and methods of use thereof. The peptide may be a subsequence of human ficolin in which case it is essentially non-toxic. Further provided is a pharmaceutical composition including such peptides. The pharmaceutical composition can include an... Agent: Metamorefix Ltd.

20120058957 - Compositions and methods for counteracting effects of reactive oxygen species and free radicals: Peptide compounds and methods for upregulating expression of a gene encoding an antioxidative enzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals are described. The peptide compounds may be used to treat or prevent diseases and conditions characterized by... Agent: Ischemix, Inc.

20120058958 - Small peptides and methods for blocking ige mediated activation of an immune cell: Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of an immune cell, a method for stabilizing the cell membrane of an immune cell, thereby preventing their further involvement in the... Agent:

20120058959 - Topical antiviral formulations: The disclosure provides novel topical antiviral pharmaceutical compositions comprising one or more antiviral compounds and 2-deoxy-D-glucose in the form of lip-balms, creams and ointments. A specific embodiment discloses a lip-balm composition comprising acyclovir and 2-deoxy-D-glucose.... Agent: Viravert LLC

20120058960 - Feedback prodrug: Compounds and methods for use in selectively inhibiting a lytic enzyme based on feedback inhibition are described. The conjugated compound serves as a substrate for a lytic enzyme. Cleavage of the conjugated compound by the lytic enzyme releases an inhibitor of the enzyme.... Agent: University Of Georgia Research Foundation, Inc.

20120058962 - Buccal and/or sublingual therapeutic formulation: A buccal and/or sublingual formulation comprising one or more active compounds; and a buccal matrix which releases the active compounds at a predetermined rate for transport across the buccal and/or sublingual membranes, wherein the rate of release of the active compounds is either (A) the same or substantially the same... Agent: Lingual Conseqna Pty Ltd.

20120058961 - Pharmaceutical composition for treating cancers: The preset invention relates to a new approach for treating cancer by using a synergistic combination of a histone deacetylase inhibitor and a furost-5-ene-3,22,26-triol glycoside. A pharmaceutical composition for treating a cancer comprising the synergistic combination and the treatment of a cancer with the synergistic combination are provided.... Agent: Henkan Pharmaceutical Co., Ltd.

20120058963 - Macrolides with anti-inflammatory activity: The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides substituted at the 4″ position, to their pharmaceutically acceptable derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their activity and use in... Agent: Glaxo Group Limited

20120058964 - Pharmaceutical formulation: Disclosed are novel formulations for the treatment of otic infections in an animal comprising a triazole anti-fungal compound, a quinolone antibiotic and a corticosteroid such as mometasone furoate monohydrate.... Agent:

20120058965 - Methods and systems for modulating hormones and related methods, agents and compositions: Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.... Agent:

20120058966 - Sphingosine kinase inhibitor prodrugs: The invention relates to prodrugs of hydroxyl-substituted adamantane compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.... Agent: Apogee Biotechnology Corporation

20120059047 - Differentiation modulating agents and uses therefor: The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including,... Agent: Verva Pharmaceuticals Pty Ltd

20120059046 - Inhibition of map4k4 through rnai: RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the... Agent: Rxi Pharmaceuticals Corporation

20120059042 - Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means: The invention relates to a nucleic acid molecule that binds and/or is complementary to the nucleotide molecule having sequence 5′-GUGGCUAACAGAAGCU (SEQ ID NO 1) and to its use in a method for inducing skipping of exon 44 of the DMD gene in a DMD patient.... Agent: Academisch Ziekenhuis Leiden

20120059048 - Methods for diagnosing and treating squamous cell carcinoma utilizing mirna-205 and inhibitors thereof: Disclosed are diagnostic and therapeutic methods related to squamous cell carcinoma. In particular, the diagnostic methods relate to detecting miRNA-205, thereby diagnosing an aggressive form of squamous cell carcinoma. The therapeutic methods relate to inhibiting the function of miRNA-205, thereby treating an aggressive form of squamous cell carcinoma.... Agent: Northwestern University

20120059041 - Methods for extending lifespan in subject: Disclosed is a method for extending lifespan in a subject. By screening for mutations that enhance resistance to multiple stresses, the invention identified multiple alleles of alpha-1, 2-mannosidase I (mas1) which, in addition to promoting stress resistance, also extended longevity. Meanwhile, longevity enhancement of a subject is also observed when... Agent: National Tsing Hua University

20120059045 - Methods of using oligomeric compounds comprising 2'-substituted nucleosides: The present disclosure provides oligomeric compounds comprising at least one 2′-fluoroethoxy modified nucleoside of formula I and methods of using these oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize... Agent: Isis Pharmaceuticals, Inc.

20120059044 - Methods of utilizing the arrestin-2/stam-1 complex as a therapeutic target: Methods of utilizing the arrestin-2/sTAM-1 complex as a therapeutic target. The methods include treating cells of a living organism to mediate an interaction between arrestin-2 and STAM-1 adapter protein molecules, wherein the interaction is characterized by the arrestin-2 adapter protein molecule directly binding to the STAM-2 adapter protein molecule. Pharmacological... Agent: Loyola University Chicago

20120059043 - Therapeutic and diagnostic strategies: The present invention encompasses the finding that microRNAs (miRNAs) regulate certain key proteins involved in DNA repair. In some embodiments, a miRNA suppresses levels and/or activity of one or more DNA repair proteins. In some such embodiments, such suppression renders cells hypersensitive to certain DNA damage agents (e.g., γ-irradiation and... Agent: Immune Disease Institute, Inc.

20120059049 - Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma: The present invention provides methods and kits for diagnosing and treating glaucoma.... Agent: Novartis Ag

20120058968 - Composition containing fermantable polysaccharides: The present invention relates to a composition to a nutritional composition comprising 0.1 to 15 gram fermentable partially hydrolysed gum having a degree of polymerisation between 10 and 300 per 100 gram dry weight of the composition and 0.1 to 15 gram fermentable, indigestible polysaccharide other than a hydrolysed gum... Agent: N.v.nutricia

20120058969 - Cystitis treatment with high dose chondroitin sulfate: Interstitial cystitis and related GAG-deficient conditions of the bladder and urinary tract are treated by instillation of high dose chondroitin sulfate, such as 400 mg/20 mL. The higher dose of chondroitin is effective for the rapid reduction of symptoms, particularly in patients with severe and otherwise recalcitrant cystitis.... Agent:

20120058967 - Vascular protecting agent having salt-absorption inhibitory activity: This invention provides a vascular protecting agent having salt-absorption inhibitory activity with the use of alginate oligosaccharide salt absorbed by the body via degradation to an oligosaccharide, so that a patient can easily and safely ingest such agent on a routine basis. A vascular protecting agent having salt-absorption inhibitory activity... Agent: Maruha Nichiro Foods, Inc.

20120058970 - Method and system for reversal of interactions between hydrophobically modified biopolymers and vesicles or cell membranes: A method for reversing gelation of hydrophobically modified biopolymer attached to vesicle or cell membranes. The gelation of hydrophobically modified biopolymer attached to vesicles or cell membranes is reversed by application of a supramolecule, such as cyclodextrin, to the gelled composition. The supramolecule disrupts the interactions between the hydrophobically modified... Agent:

20120058971 - Cyclodextrin-based polymers for therapeutic delivery: Methods and compositions relating to CDP-taxane conjugates are described herein.... Agent: Cerulean Pharma Inc.

20120058972 - Novel use: The present invention relates to the use of a galactooligosaccharide in the prevention or treatment of an inflammatory disorder, in particular an intestinal inflammatory disorder.... Agent:

20120058973 - Compositions comprising a silicone water-in-oil emulsifier and a low nitrogen containing amino-functional silicone gum: Provided are compositions comprising a silicone water-in-oil emulsifier, a low nitrogen containing amino-functional silicone gum, a hydrophobic agent, a non-silicone primary emulsifier, and water.... Agent:

20120058974 - Composition comprising pesticide and benzotriazole uv absorbers: The present invention relates to an agrochemical composition comprising pesticide and UV absorber. The invention furthermore relates to UV-absorbers and to the use thereof in agrochemical compositions. It moreover relates to a method of controlling phytopathogenic fungi and/or undesirable plant growth and/or undesirable insect or mite infestation and/or of regulating... Agent: Basf Se

20120058975 - Phosphonate compounds: The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.... Agent: The Regents Of The University Of California

20120058976 - Phosphonate ester derivatives and methods of synthesis thereof: The disclosure describes methods of synthesis of phosphonate ester derivatives. Preferred methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of phosphonate ester derivatives without the use of chromatographic... Agent: Chimerix, Inc.

20120058977 - Pharmaceutical compositions and methods for treating tuberculosis: A pharmaceutical composition for the treatment of a disease caused by a bacterium that belongs to the group of nocardioform actinomycetes, said composition comprising an effective amount of a compound selected from compound I, (+)-compound II, (−)-compound II, compound III, or mixtures thereof.... Agent: Rijksuniversiteit Groningen

20120058980 - Aerosol formulation for the inhalation of beta agonists: p

20120058978 - Method for the treatment of central nervous system cancers and compositions related thereto: Use of compounds disclosed herein, typically progesterone or analog or derivative thereof, in the treatment of central nervous system cancers, specifically neuroblastoma and glioblastoma is provided. The treatment offers a reduced toxicity as compared to the currently available chemotherapeutic agents. The progesterone may be administered alone or in combination with,... Agent: Emory University

20120058979 - Methods and reagents for the treatment of immunoinflammatory disorders: The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination... Agent: Zalicus Inc.

20120058981 - Androgen pharmaceutical composition and method for treating depression: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a... Agent:

20120058982 - Analogs of benzoquinone-containing ansamycins and methods of use thereof: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase... Agent: Infinity Pharmaceuticals, Inc.

20120058984 - Pyrimidine derivatives used as itk inhibitors: e

20120058985 - Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities:

20120058986 - Di-azetidinyl diamide as monoacylglycerol lipase inhibitors:

20120058987 - Therapeutic uses of quinazolinedione derivatives: The subject matter of the present invention is the use of compounds of formula (I) in the form of a base, a hydrate or a solvate, or of mixtures thereof, as a medicament or for preparing a medicament intended for the treatment and/or prevention of disorders associated with the central... Agent: Sanofi

20120058983 - Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension: The present invention relates to the use of selective adenosine A1 agonists, in particular the dicyanopyridines of formula (I), for the treatment and/or prophylaxis of glaucoma and ocular hypertension as well as the their use for the production of a medicament for the treatment and/or prophylaxis of glaucoma and ocular... Agent: Bayer Pharma Aktiengesellschaft

20120058988 - Carbazole and carboline kinase inhibitors: e

20120058989 - Antibacterial fluoroquinolone analogs:

20120058990 - Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid: Abstract Compounds of a formula entitled, trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof, hydrate, and hydrate in crystalline form; pharmaceutical formulations; and methods of use are disclosed.... Agent: Eli Lilly And Company

20120058991 - Formulations and methods of administration of cephalotaxines, including homoharringtonine: The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of homoharringtonine for the treatment of cancer and other aberrant cellular diseases. The invention also provides... Agent: Chemgenex Pharmaceuticals, Inc.

20120058992 - Therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis: The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, the invention relates to combined therapies that modulate angiogenesis for treating said disease.... Agent: Pharnext

20120058993 - Stable suspension formulation: A physicochemically stable aqueous composition including clozapine suspension.... Agent: Douglas Pharmaceuticals Ltd.

20120058994 - Novel compounds: The invention relates to the novel salts AB of the base A with a physiologically acceptable acid B which is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, fumaric acid and silcylic acid and the polymorphic compounds, the corresponding solvates and hydrates thereof.... Agent: Boehringer Ingelheim International Gmbh

20120058995 - Methods of chemical synthesis of diaminophenothiazinium compounds involving the use of persulfate oxidants: This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the e//i method comprises the steps of in... Agent: Wista Laboratories Ltd.

20120058996 - Carbazole carboxamide compounds useful as kinase inhibitors: i

20120058997 - Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors:

20120058998 - Compounds, compositions and methods for the treatment of inflammatory diseases: R is a C1-C10 alkylene group, in which, when the number of carbon atoms is at least 2, there are optionally 1 or 2 non-adjacent double bonds; 1 to 3 non-adjacent methylene groups are optionally replaced by NR1 (where R1 is H, alkyl, or acyl), O, or S; and 1... Agent:

20120058999 - Substituted tetrahydropyrrolopyrazine compounds: Tetrahydropyrrolopyrazine compounds, methods for their preparation, pharmaceutical compositions containing such compounds, and a method of using such compounds for the treatment of pain and other conditions mediated at least partially by Bradykinin 1 receptors (B1R).... Agent: Gruenenthal Gmbh

20120059000 - Chemical compounds, compositions and methods for kinase modulation: Chemical compounds that modulate kinase activity, including PI3 kinase activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.... Agent:

20120059001 - Novel kinase modulators: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.... Agent: Rhizen Pharmaceuticals Sa

20120059003 - Inhibitors of inv(16) leukemia: This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ˜12% of acute myeloid leukemia (AML). The inv(16) fusion results in expression of the CBFβ-SMMHC fusion protein in the blood cells of afflicted patients. The present invention provides compounds which inhibit the... Agent: University Of Virginia Patent Foundation

20120059002 - Novel anti-inflammatory agents: Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring... Agent:

20120059004 - Compounds and compositions for treating cancer: The invention relates to compounds and composition for the treatment and prevention of cancer. The invention also covers all diseases that may be treated by selective modulation of levels of reactive oxygen species in diseased cells versus normal cells. Methods for the preparation and administration of such compositions are also... Agent: Canthera Therapeutics, Inc.

20120059005 - Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) an antidiabetic compound for use in the treatment of proliferative diseases: The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) an insulin sensitivity enhancer compound for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation... Agent: Novartis Ag

20120059006 - Sigma receptor inhibitors: e

20120059008 - Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders: The present embodiments are related to the compound of Formula 1 or Formula 2 below and pharmaceutical formulations thereof as well as treatments for a wide variety of Central Nervous System disorders with the pharmaceutical formulations. Some embodiments include the use of a variety of the instant compounds which surprisingly... Agent: Cenerx Biopharma, Inc.

20120059007 - Pharmacologically-active vanilloid carbamates: This application relates to pharmacologically-active vanilloid compounds which are useful for the treatment of various anti-inflammatory states characterized by inhibition of FAAH, such as, Alzheimer's dementia, Parkinson's disease, depression, pain, rheumatoid arthritis, pathophysiology of mood disorders, multiple sclerosis, and inflammation, or antagonism of TRPV1, such as, for example, Huntington's disease,... Agent:

20120059009 - Anti-tumor agent containing tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin: i

20120059010 - Alpha-helix mimetics and methods relating to the treatment of fibrosis: The invention provides α-helix mimetic structures and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate to the treatment of diseases including fibrosis, such as pulmonary fibrosis.... Agent: Institute For Chemical Genomics

20120059012 - 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof: e

20120059011 - Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone: This invention relates to pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and pioglitazone, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.... Agent:

20120059014 - Compounds for the treatment of metabolic disorders: i

20120059015 - Novel spiroheterocyclic compounds as mglu5 antagonists: The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering... Agent: Recordati Ireland Ltd.

20120059013 - Method of treating early morning akinesia in subjects having parkinson's disease: The present invention provides a method for treating early morning akinesia, comprising continuous administration to a patient in need of such treatment a therapeutically effective amount of a dopamine agonist or a pharmaceutically acceptable salt, enantiomer, solvate, hydrate, polymorph or prodrug thereof.... Agent: Boehringer Ingelheim International Gmbh

20120059017 - Cgrp receptor antagonist: The disclosure generally relates to the compound of formula I, (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide, including pharmaceutically acceptable salts, which is a CGRP-receptor antagonist. The disclosure also relates to pharmaceutical compositions and methods for using the compound in the treatment of CGRP related disorders including migraine headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory... Agent: Bristol-myers Squibb Company

20120059016 - Piperidine and piperazine derivatives as autotaxin inhibitors: The present invention relates to piperidine and pyrazine derivatives according to formulae (Ia), (Ib) and (II) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of... Agent:

20120059018 - Novel chlorin e6-folic acid conjugate, preparation method thereof, and a pharmaceutical composition for the treatment of cancer comprising the same: The present invention relates to a novel chlorin e6-folic acid conjugate, a preparation method thereof, and a pharmaceutical composition for the treatment of cancer comprising the same, and more particularly, to a novel compound prepared by linking chlorin e6 to folic acid, which effectively produces singlet oxygen in various media... Agent: Diatech Korea Co., Ltd.

20120059019 - Compounds for the treatment of hepatitis c: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Agent: Bristol-myers Squibb Company

20120059020 - Prophylactic or therapeutic agent for pulmonary fibrosis: Disclosed is a compound which has an inhibitory activity on plasminogen activator inhibitor-1 (PAI-1) and has a propanedioic acid structure represented by formula (1) [wherein R1 and R2 independently represent a hydrogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms; R3 represents a cyclohexyl... Agent: Shizuoka Coffein Co., Ltd

20120059021 - Compositions and methods for treating cancer and methods for predicting a response to such treatments: The present disclosure relates to the regulation and function of the Wnt/β-catenin signaling pathway and the ERK signaling pathway. The disclosure provides methods of treatment for melanoma by administering both an inhibitor of ERK signaling and an activator of Wnt/β-catenin signaling. These methods may be used alone or in combination... Agent: University Of Washington

20120059022 - Crystalline form of bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoicacid] calcium salt: Two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors are described.... Agent:

20120059023 - Use of polymorphic forms of rifaximin for medical preparations: The present invention relates to Rifaximin polymorphic forms α, β and γ, to their use in medicinal preparations for the oral or topical route and to therapeutic methods using them.... Agent: Alfa Wassermann, S.p.a.

20120059024 - Drug abuse deterrent, methods and compositions: The present invention relates generally to the field of pain management. More particularly, the present invention relates to analgesic combinations of an opioid and flupirtine or retigabine which reduce the risk of substance abuse in pain management. Such combinations are referred to as abuse-deterrent fixed dose combinations (FDC).... Agent: Relevare Aust. Pty Ltd

20120059025 - Dry powder compound formulations and uses thereof: The present invention provides lyophilized formulations comprising methylnaltrexone, and processes for preparation of provided formulations. Additionally provided are compositions and products containing the methylnaltrexone formulation, as well as methods for producing formulations, compositions and products. Provided formulations as well as compositions and products containing methylnaltrexone formulations are useful for preventing,... Agent: Wyeth

20120059026 - Antimicrobial agents: The invention provides a compound of formula (I): or a salt or prodrug thereof, wherein Y, W, Z, Z1, Z2, Z3, Z4, and R1-R12 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as antibacterial agents.... Agent: Rutgers, The State University Of New Jersey

20120059027 - Tacrolimus injection preparation: A tacrolimus injection preparation comprising tacrolimus, polyoxyethylene castor oil (35), and non-aqueous solvent is disclosed. Preferably the weight ratio of polyoxyethylene castor oil (35) to tacrolimus in the injection preparation is 0-20:1. The injection preparation significantly decreased the clinical risk.... Agent: Fuzhou Harvester Pharmaceutical R&d Co., Ltd.

20120059028 - Thieno [2, 3-b] pyridine derivatives as viral replication inhibitors: The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention... Agent: Katholieke Universiteit Leuven

20120059030 - Heterocyclic compound and use thereof: e

20120059029 - Selective integrin inhibitors: This invention provides methods for selectively antagonizing the α4β1 integrin heterodimer in a subject in need thereof, and preferably in a human subject. The methods of the invention utilize conjugates comprising two or more α4β1 small molecule antagonists covalently attached to a biocompatible polymer. These methods of selectively inhibiting α4β1... Agent: Elan Pharmaceuticals, Inc.

20120059031 - Combinations comprising antimuscarinic agents and pde4 inhibitors: A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.... Agent:

20120059032 - 1,2,3,4-tetrahydroisoquinoline derivatives effective as antiglioma agents, methods of making, and their use: Disclosed are tetrahydroisoquinoline-derivative compounds effective for killing cancer cells, shrinking tumor size, and treating cancer.... Agent: University Of Tennessee Research Foundation

20120059033 - Crystalline salts of a potent hcv inhibitor: This invention relates to novel tris(hydroxymethyl)aminomethane, choline and N-methyl-D-glucamine salt forms of the following Compound (1) and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:... Agent: Boehringer Ingelheim International Gmbh

20120059035 - Method of predicting a predisposition to qt prolongation: The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound... Agent: Vanda Pharmaceuticals, Inc.

20120059034 - Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation: The invention relates to novel crystalline hydrate, amorphous and crystalline polymorphic forms of 2-[4-(4-Fluoro-benzyl)-piperidine-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazole-6-yl)-acetamide (I) (radiprodil). Processes for the preparation of these forms, compositions containing these forms, and methods of use thereof are also described.... Agent:

20120059036 - Method for reducing thrombocytopenia and thrombocytopenia-associated mortality: Disclosed are methods for reducing the risk of thrombocytopenia-associated mortality and morbidity, and for reducing the risk of becoming thrombocytopenic, in patients whose treatment requires inhibition of platelet aggregation. The methods involve administration of a pharmaceutically acceptable salt of tirofiban.... Agent:

20120059037 - Substituted pyridine derivatives and their medical use: The present application discloses novel substituted pyridinyl-methylamine derivatives and their use as modulators of the voltage gated Kv7 (KCNQ) potassium ion channels. In other aspects the application discloses the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising these compounds.... Agent: Neurosearch A/s

20120059039 - Anti-shock agent comprising diaminotrifluoromethylpyridine derivative: e

20120059038 - Polyketide compound: Capnodiaceae strain No. 339855 was collected and a polyketide compound was isolated from the cultural solution thereof It was confirmed that the polyketide compound or a salt thereof has a potent anti-Trichophyton activity and is useful as a pharmaceutical, particularly as an agent for treating trichophytosis, thereby completing the present... Agent: Astellas Pharma Inc.

20120059040 - Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid magnesium: Novel forms of atorvastatin magnesium salt designated Form A, Form B, Form C, Form D, Form E, and Form F, pharmaceutical compositions containing such compounds, methods for their preparation and methods utilizing the compounds for treatment of hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease are described.... Agent: Pfizer Inc

20120059050 - Garcinia derivative, its preparing method and medicinal use: The present invention relates to a field of pharmaceutical chemistry, more specifically, the present invention relates to a garcinia derivative Formula (I), its preparing method, and medicinal use. Wherein the definitions of R1 and R2 are disclosed in the specification of the present invention, and the derivative of the present... Agent:

20120059051 - Oral composition containing egcg and lycopene: Composition containing the combination of (−)-epigallocatechin gallate (EGCG) and lycopene characterized in that the ratio of EGCG to lycopene is in the range of 100:1 to 1:1.... Agent: DsmIPAsset B.v.

20120059052 - Prenylflavonoid formulations: Methods and formulations for increasing the water solubility and/or bioavailability of prenylfiavonoids are disclosed. The formulations may be employed to treat a disease states, including cancer.... Agent: Bioactives, Inc.

20120059053 - Compounds of 2,3-dihydro-benzofuran: This invention provides new 2,3-dihydro-benzofuran compounds, their use for the treatment or prevention of melatoninergic disorders and its compositions.... Agent: Ferrer International, S.a.

20120059054 - Use of copolymers based on amino-containing polymers as matrix binders in preparing active compound-containing granules and administration forms: i

20120059055 - N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.... Agent: Panmira Pharmaceuticals, LLC

20120059056 - Carbonate derivatives as skin care: Carbonates of anti-aging ingredients, in particular anti-oxidants and skin illuminating phenol ingredients, have been prepared as derivatives of these ingredients with enhanced physical properties. It has been demonstrated that these carbonates will hydrolyze under enzymatic catalysis to release the parent ingredient. In contrast, esters of the phenolic groups in many... Agent: Eastman Chemical Company

20120059057 - Antiviral treatments: The invention provides unit dosage forms, kits, and methods useful for treating viral infections.... Agent: Biocryst Pharmaceuticals, Inc.

20120059058 - Dispersions of rasagiline citrate: The subject invention provides a solid dispersion of rasagiline citrate, a composition and a process for the manufacture thereof.... Agent:

20120059059 - Method for inhibiting activity and/or expression of matrix metalloproteinase, inhibiting phosphorylation of mitogen-activated protein kinase, and/or promoting expression of collagen using tormentic acid: A method for inhibiting the activity of matrix metalloproteinase (MMP), inhibiting the expression of matrix metalloproteinase, inhibiting the phosphorylation of mitogen-activated protein kinase (MAPK), and/or promoting the expression of collagen in a mammal is provided. The method comprises administrating to the mammal an effective amount of an active component selected... Agent:

20120059060 - Valproic acid drug delivery systems and intraocular therapeutic uses thereof: Biocompatible, bioerodible, sustained release drug delivery system formulated as implants, microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer, the system being effective, when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or... Agent: Allergan, Inc.

20120059061 - Novel anti-inflammatory compounds: An object of the present invention is to provide a compound having a novel structure for overcoming the defects of conventional steroid agents and NSAIDs. It is found that the particular dihydroxy bodies of eicosapentaenoic acid and docosahexaenoic acid, which have not conventionally been known (11,18-dihydroxy eicosapentaenoic acid (11,18-diHEPE), 17,18-dihydroxy... Agent: The University Of Tokyo

20120059062 - Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions: Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of cannabis plants are presented which are rich in these substances and suitable for pharmaceutical use.... Agent: Gw Pharma Limited

20120059063 - Combinations of adapalene and benzoyl peroxide for treating acne lesions: Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by... Agent: Galderma Research & Development

20120059064 - Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase: The present invention is directed to methods of modulating the activity of an isoform of manganese superoxide dismutase which is useful for the treatment of diseases such as neurodegenerative diseases and heart failure.... Agent: Mitotek, LLC

20120059065 - Tamper resistant dosage form comprising an anionic polymer: e

20120059066 - Pharmaceutical salts: The invention relates to pharmaceutical salts comprised of a pharmaceutical active substance and of at least one sugar substitute, to medicaments containing these salts, and to the use of these salts for producing medicaments.... Agent: Grunenthal Gmbh

20120059067 - 1-acetyl-5-hydroxyanthracene-9,10-dione for treatment of retinal disease: A composition may include a pharmaceutical carrier and an amount, therapeutically effective for the treatment of a retinal disease, of CLT-005 (1-acetyl-5-hydroxyanthracene-9,10-dione), wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization, and wherein the composition is prepared for administration topically. The composition may be... Agent: Charlesson, LLC

20120059068 - Composition based on zeolite and usage as lick stone: The invention lies in the field of environmental technology and relates to a compound, in particular for the use, in particular as metabolically inert gas absorber for ruminants on the basis of zeolite, salt and a binding agent. It furthermore relates to a licking element with such a composition, a... Agent: Triple-s Pte Ltd

20120059069 - Amphiphilic branched copolymer, methods of preparation, emulsions, and uses: e

20120059070 - Powderous formulations of fat-soluble active ingredients: Stable powderous formulations containing a fat-soluble active ingredient, e.g., vitamin A, in a matrix of a native lupin protein composition are disclosed.... Agent:

20120059071 - High-purity mogrosides and process for their purification: The present invention provides a process for preparation of highly purified mogrosides mixture from low purity mogrosides mixture. The process comprises providing a mixture of low purity mogrosides, dissolving the low purity mogrosides mixture in water or an aqueous alcohol solution to form an initial solution of mogrosides, passing the... Agent: Purecircle Sdn Bhd

  
03/01/2012 > 142 patent applications in 109 patent subcategories. listing by industry category

20120053112 - Methods and compositions related to the regulation of goblet cell differentiation, mucus production and mucus secretion: Disclosed are methods and compositions related to the regulation of goblet cell differentiation, mucus production and mucus secretion. In some embodiments, methods for the treatment of mucus hyperproduction, methods for the treatment of pulmonary inflammation, methods of screening compounds, compositions for the treatment of mucus hyperproduction, or compositions for the... Agent: Children's Hospital Medical Center

20120053113 - Manufacture of inter-alpha-inhibitor (iaip) from plasma: The present invention provides compositions and pharmaceutical formulations of IaIp derived from plasma. Also provided are methods for the manufacture of the IaIp compositions and formulations, as well as method for the treatment of diseases associated with IaIp dysfunction.... Agent: Baxter International Inc.

20120053114 - Method: The invention provides methods of screening test compounds for their ability to reduce retention of atherogenic lipoproteins in atherogenesis by measuring their activity as a modulator of the binding affinity of CEL (Carboxyl Ester Lipase) to various receptors. The invention further provides methods for the use of active modulators of... Agent:

20120053115 - Lantibiotic carboxyamide derivatives with enhanced antibacterial activity: The present invention relates to novel amide derivatives of the lantibiotic 97518 and their uses. In particular, the present invention describes novel compounds having general formula (II) and their use as antibiotic.... Agent: Sentinella Pharmaceuticals, Inc.

20120053116 - Scytovirin domain 1 related polypeptides: A scytovirin domain 1 (SD1) polypeptide, a nucleic acid encoding the polypeptide, and related fusion proteins, conjugates, isolated cells, vectors, and antibodies, as well as a method of inhibiting a viral infection using the same.... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services

20120053117 - Pharmaceutical composition, drug screening method and method for treating malaria: The present invention relates to the use of serpentine receptors existent in parasites of genus Plasmodium for treating malaria.... Agent: Universidade De Sao Paulo-usp

20120053118 - Methods for affecting body composition using amylin agonists: Methods for affecting body composition include the use of amylin agonists, such as pramlintide or davalintide. Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.... Agent: Amylin Pharmaceuticals, Inc.

20120053119 - Therapeutic method for increasing pancreatic beta cell mass: The present invention provides various methods for increasing beta cell mass. In certain embodiments, such methods include steps of administering to a subject an effective amount of: (a) SDF1, a polypeptide having amino acid sequence substantially homologous thereto, or a fragment thereof capable of increasing beta cell survival; and (b)... Agent:

20120053120 - Treatment of subarachnoid hemorrhage with apo e analogs: Novel ApoE peptide derivatives and ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including subarachnoid hemorrhage, intracerebral hemorrhage, and intraventricular hemorrhage and other brain disorders. The invention encompasses methods for treating cerebral vasospasm by administration of at least one ApoE or ApoE mimetic peptide.... Agent: Cognosci, Inc.

20120053121 - Administration of hb-egf for the protection of enteric neurons: The invention provides for methods of protecting neurons within the enteric nervous system (ENS) comprising administering an EGF receptor agonist, such as heparin-binding EGF (HB-EGF). These methods include reducing damage of ENS neurons in patient s suffering from an intestinal injury. In addition, the invention provides for increasing intestinal motility... Agent: Nationwide Children's Hospital, Inc.

20120053122 - Method for the prophylaxis or treatment of flushing: The present invention relates to a method for the prophylaxis or treatment of a subject for flushing, wherein a pharmaceutical agent having LHRH antagonistic activity is administered to said subject at a dosage of less than 15 μg/kg/day. The present invention also relates to a pharmaceutical agent having LHRH antagonistic... Agent: Maatschap Interne Geneeskunde Rijnstate

20120053123 - Natriuretic polypeptides having mutations within their disulfide rings: Materials and Methods related to making and using natriuretic polypeptides having a mutation in the ring portion of their structure.... Agent: Mayo Foundation For Medical Education And Research

20120053124 - Binder for c-reactive protein: A polypeptide dimer is provided wherein both protomers have a sequence according to SEQ ID NO: 1 and at least one phosphocholine derivative is attached to the polypeptide. The polypeptide shows a specific binding for C-reactive protein (CRP). The utilization of the polypeptide in assays for determining the concentration of... Agent: Modpro Ab

20120053125 - Phosphatase inhibitor protein-1 as a regulator of cardiac function: The present invention relates to novel nucleic acids which encode novel mutant forms of Inhibitor Protein-1 (I-1). In particular, the I-1 mutant forms comprise altered phosphorylation sites of PKC-α. In addition, the present invention relates to methods of regulating cardiac contractility and function, and for treatment of cardio myopathy and... Agent: The University Of Cincinnati

20120053126 - Injection paradigm for administration of botulinum toxins: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin... Agent: Allergan, Inc.

20120053127 - Targeted delivery of botulinum toxin to the sphenopalatine ganglion: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.... Agent: Allergan, Inc.

20120053128 - Method of inhibiting angiogenesis: A method of inhibiting angiogenesis in mammals using introduction of an 18 amino acid tandem-repeat dimer peptide of apolipoprotein E residues 141-149 into the mammal, in an amount effective to inhibit angiogenesis in the mammal compared to the rate of angiogenesis which would occur in the mammal in the absence... Agent: Xavier University

20120053129 - Target-activated cell/tissue-penetrating peptide for delivery of impermeable compounds and use thereof: The present invention relates to a target-activated cell/tissue-penetrating peptide for delivery of impermeable compounds (Target Activated Cell/tissue Translocation peptide for Impermeable Compound Strategy (TACTICS)), and the use thereof, and more particularly to a target-activated cell/tissue-penetrating peptide, which comprises (a) a protein transduction domain (PTD), (b) a masking domain and (c)... Agent: Nano Intelligent Biomedical Engineering

20120053130 - Composition for enhancing absorption of a drug and method: e

20120053131 - Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy: Disclosed are methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient In one embodiment, disclosed is a method of prognosing ulcerative colitis in an individual by determining the presence or absence of one or more risk variants, where the presence of one or more risk... Agent: Cedars-sinai Medical Center

20120053133 - Antiseptic agent composition: A novel antiseptic agent composition which has a wide antimicrobial spectrum and excellent antiseptic properties is provided. An antiseptic agent composition A contains a glycerin hydroxy fatty acid monoester that is an ester of glycerin and a hydroxy fatty acid having 8 to 18 carbon atoms, and a specific antiseptic... Agent: Taiyo Corporation

20120053132 - Compositions and methods for inhibiting cytochrome p450: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect... Agent: Sequoia Pharmaceuticals, Inc.

20120053134 - Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases: The pharmaceutical composition repairs nerve tissue damaged by herpes zoster to reduce the acute pain caused by herpes zoster, prevents postherpetic neuralgia, and enables a fundamental treatment through the recovery of nerve tissue in the postherpetic neuralgia. Further, the pharmaceutical composition can be effectively used for neuronal damage, including sciatic... Agent:

20120053135 - Drug composition for treating chronic liver disease and its application: A drug composition for treating chronic liver diseases, consists of: Astragalus Astragalosides and Glycyrrhiza Acid by weight ratio of 3˜6:1. By testing and validating with classic animal model, the results confirmed that the drug composition of the present invention can significantly reduce the collagen content of rat liver, and reduce... Agent: Shuguang Hospital Affiliated With Shanghai University Of Traditional Chinese Medicine

20120053136 - Diagnosis and treatment of drug-resistant ewing`s sarcoma: Disclosed herein are diagnostic and prognostic methods for determining drug sensitivity and resistance in Ewing's sarcoma patients. Treatments for drug-resistant Ewing's sarcoma are also disclosed. The assays involve the detection of GSTM4 gene expression alone or in combination with other clinical factors. The tests are suitable for diagnosing and monitoring... Agent:

20120053138 - Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments: The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from... Agent: Unigen, Inc.

20120053137 - Method for treating addiction using quercetin-containing compositions: This invention relates to a method of treating addiction using a composition containing quercetin. Preferably, it also contains vitamin B3, and vitamin C.... Agent: Quercegen Pharmaceuticals LLC

20120053139 - Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors: i

20120053140 - Administration of avermectin/milbemycin compounds for the treatment of ophthalmic pathologies: Administration of at least one compound of the family of the avermectins or of the family of the milbemycins, notably ivermectin, is useful for the treatment of ophthalmic pathologies, including ocular rosacea.... Agent: Galderma S.a.

20120053142 - Compositions and methods for minimizing and/or reducing the appearance of defects around eyes: The invention relates to compositions comprising at least one xanthine compound, preferably further comprising at least one agent which acts on capillary circulation and/or at least one natural moisturizing agent, which can be used to treat, or to reduce and/or minimize the appearance of, defects such as dark circles, bags... Agent: L'oreal S.a.

20120053141 - Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis: The present invention pertains to novel uses of glycyrrhetinic acid (GA), glycyrrhizic acid (GLA) and related compounds for prevention and/or treatment of pulmonary fibrosis, in particular, irradiation-induced pulmonary fibrosis. Also embodied are therapeutic uses of prodrugs, metabolites, derivatives (e.g., acids, esters and ethers), and salts of glycyrrhetinic acid (GA) and... Agent:

20120053225 - Akt tyrosine 176 phosphorylation cancer biomarker: AKT/PKB kinase is a key signaling component of one of the most frequently activated pathways in cancer and is a major target of cancer drug development. The present study uncovered that growth factors binding to RTKs lead to activation of a non-receptor tyrosine kinase, Ack1 (TNK2), which directly phosphorylates AKT... Agent: H. Lee Moffitt Cancer Center And Research Institute, Inc.

20120053224 - Compositions and methods for micro-rna expression profiling of cancer stem cells: The present invention relates compositions and methods for microRNA expression profiling of cancer stem cells. In particular, the invention relates to a method for identifying and/or diagnosing one or more cancer stem cells, the method comprising identifying from a plurality of nucleic acid molecules, each encoding a microRNA sequence, one... Agent: Universitat Regensburg

20120053223 - Compositions and methods for treating retrovirus infections: The present invention relates to at least one nucleic acid (i) comprising or consisting of or (ii) encoding a nucleic acid comprising or consisting of, a sequence selected from the group consisting of: 1) SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO:... Agent: Centre National De La Recherche Scientifique (c.n.r.s)

20120053226 - Design of oligonucleotide analogs as therapeutic agents: e

20120053227 - Mir-33 inhibitors and uses thereof: The miRNA miR-33 is shown to inhibit the expression of carnitine O-octaniltransferase (CROT), Carnitine palmitoyltransferase 1A (CPT1a) and hydroxyacyl-CoA-dehydrogenase (HADHB), reduce fatty acid oxidation in hepatic cells, and target the insulin receptor substrate 2 (IRS-2) independent of its ability to elevating plasma high density lipoprotein (HDL) levels. MiR-33 inhibitors are... Agent: New York University

20120053231 - Prevention and treatment of nosema disease in bees: Compositions and methods for reducing susceptibility and enhancing tolerance to Nosema disease (Nosemosis) using RNA interference technology, and more particularly, prevention and treatment of Nosema infections in honeybees by feeding of Nosema-specific dsRNA.... Agent:

20120053229 - Regulation of mir-33 micrornas in the treatment of cholesterol-related disorders: Compositions comprising nucleic acid sequences that target MiR-33 microRNAs are described, together with uses of the same in the treatment of cholesterol-related disorders.... Agent: The General Hospital Corporation

20120053228 - Splice-region antisense composition and method: Antisense compositions targeted against an mRNA sequence coding for a selected protein, at a region having its 5′ end from 1 to about 25 base pairs downstream of a normal splice acceptor junction in the preprocessed mRNA, are disclosed. The antisense compound is RNase-inactive, and is preferably a phosphorodiamidate-linked morpholino... Agent: Avi Biopharma, Inc.

20120053230 - Treatment of neurological disorders by dsrna administration: The present invention relates to methods to treat neurological disorders comprising intrathecal injection of an effective amount of a double-stranded (ds) RNA into a subject in need, wherein the dsRNA inhibits the expression of a target gene and to pharmaceutical compositions useful for such treatment.... Agent: Novartis Ag

20120053233 - Gene transfer agent composition containing polyamidoamine dendron: The present invention provides a gene transfer agent, a gene transfer kit, and a gene transfer method excellent in safety and transfer efficiency. Specifically, the present invention provides a gene transfer agent composition, the gene transfer agent composition including a compound represented by any one of the following formulae DL-G1... Agent: Public University Corporation Osaka Prefecture University

20120053234 - Hepcidin binding nucleic acids: The present invention is related to a nucleic acid capable of binding to hepcidin.... Agent: Noxxon Pharma Ag

20120053232 - Isolated genomic polynucleotide fragments from the p15 region of isolated genomic polynucleotide fragments from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 4 (tssc4): Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human and tumor suppressing subtransferable candidate 4 (TSSC4) and methods of use.... Agent: Ryogen LLC

20120053143 - Triacetyl-3-hydroxyphenyladenosine and its use for regulating blood fat: The invention discloses triacetyl-3-hydroxyphenyladenosine represented by formula (I), the preparation, the pharmaceutical composition and the use thereof. Specially, the invention discloses a new compound of 2′,3′,5′-tri-O-acetyl-N6-(3-hydroxyphenyl)adenosine. Using hypoxanthine nucleoside as starting material, the compound is prepared by acetylating with acetic anhydride, chlorinating with thionyl chloride, and being substituted with 3-hydroxy... Agent: Institute Of Mataria Medica, Chinese Academy Of Medical Sciences

20120053144 - Cobalamin taxane bioconjugates for treating eye disease: The present invention is directed to methods of treating eye disease. In one embodiment, the method can comprise administering a bioconjugate to a subject to treat the eye disease, where the bioconjugate comprises a taxane covalently bonded to a cobalamin. Additionally, the bioconjugate can be dissolved in an aqueous solution... Agent: Osiris Therapeutics, Inc.

20120053145 - Aripiprazole complex formulation and method: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or... Agent: Bristol-myers Squibb Company

20120053146 - Pesticidal compositions:

20120053147 - Thiazolopyrimidinone derivatives as pi3 kinase inhibitors:

20120053148 - Inhibitors of hepatitis c virus: The present application includes novel inhibitors of HCV, compositions containing such compounds, therapeutic methods that include the administration of such compounds.... Agent: Gilead Sciences, Inc.

20120053149 - Thiazole derivatives and their use as p2y12 receptor antagonists: The present invention relates to thiazole derivatives of formula I and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.... Agent:

20120053150 - N-pyrazolyl carboxamides as crac channel inihibitors: The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.... Agent:

20120053151 - Dimethoate low voc formulations: Liquid dimethoate formulations comprising a solvent chosen among liquids comprised of a compound having a ethylenglycol-propylenglycol co-polymeric chain as well as mixtures thereof. These solvents diminish the use of VOC solvents while still providing storage stable formulations.... Agent: Cheminova A/s

20120053152 - (r)-(-)-1,2-propanediol compositions and methods: Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an... Agent:

20120053153 - Topical gel formulation comprising organophosphate insecticide and preparation thereof: The present invention provides a topical gel pharmaceutical formulation of insecticide suitable for treating an ectoparasite in a mammal, comprising: a) about 0.1-10% by weight of an insecticide; b) at least about 75% by weight of an organic solvent selected from the group consisting of a lower alkyl alcohol, a... Agent: Taro Pharmaceuticals North America, Inc.

20120053154 - Composition and method for inhibiting biogenic sulfide generation: Compositions and methods for inhibiting sulfide biogeneration from biofilms are described, as well as methods for preparing the compositions. The compositions comprise anthrahydroquinone and a biocide. The compositions may also include anthraquinone.... Agent: Arkion Life Sciences

20120053155 - System and method for reverting antibiotic tolerance of bacterial persister cells: A system and method for reverting the antibiotic tolerance of persister cells. Brominated furanones, which are quorum sensing inhibitors, are used to revert the antibiotic tolerance of persister cells and enhance their susceptibility to antibiotics by up to one hundred fold. Brominated furanones can be used against bacterial persister cells... Agent: Syracuse University

20120053156 - Compositions and methods for loop diuretics with consistent bioavailability: Diuretic bioactivity profiles of phase inversion micronized furosemide and furosemide co-precipitated with Eudragit L100, and mixtures of those formulations with stock furosemide, reduced or eliminated the rapid spike in diuresis associated with immediate release formulations and maintained cumulative urine output. Of the formulations tested, each of a mixture of micronized... Agent: Brown University

20120053157 - Methods for the treatment or prophylaxis of thrombosis or embolism: The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (S)oxo-clopidogrel or its derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism... Agent: Ipca Laboratories Limited

20120053158 - Preparation of an acetyl salicylic acid/glutamic acid complex for oral administration: The present invention refers to a pharmaceutical preparation comprising an ionic type complex of acetyl salicylic acid and L-glutamic acid for use in the prevention or reduction of side-effects on stomach tissue associated with an oral administration of acetyl salicylic acid.... Agent:

20120053160 - Dosage form for hormonal contraception: A dosage form for hormonal contraception containing a specific number of gestagen-containing daily units A and a specific number of gestagen-containing daily units B for uninterrupted, daily, oral administration of daily units A and then immediately subsequently of daily units B, wherein the daily units A in each case contain... Agent: Gruenenthal Gmnh

20120053159 - Isotopologues of lenalidomide: Provided herein are lenalidomide, which is enriched with isotopes such as deuterium. Pharmaceutical compositions comprising the isotopes-enriched compounds, and methods of using such compounds are also provided.... Agent:

20120053161 - Topical solution formulations containing a corticosteroid and a cyclodextrin: Solution formulations containing a corticosteroid, cyclodextrin, and xanthan gum are disclosed. The formulations are intended for topical application to the eye, ear, or nose.... Agent: Novartis Ag

20120053162 - Certain chemical entities, compositions, and methods: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.... Agent:

20120053163 - Steroids as agonists for fxr: e

20120053164 - Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. Formula (I), wherein A is selected from among a single bond, ═CH—, —CH2—, —O—, —S—, and —NH—; wherein n... Agent: Boehringer Ingelheim International Gmbh

20120053165 - Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.... Agent: Pfizer Inc.

20120053166 - 4-oxadiazol-2-yl-indazoles as inhibitors of p13 kinases: m

20120053167 - Triazine derivatives as kinase inhibitors: A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.... Agent: Ucb Pharma, S.a.

20120053168 - Fused benzoazepines as neuronal nicotinic acetylcholine receptor ligands: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with... Agent: Targacept, Inc.

20120053169 - Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury: Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt of either of the foregoing and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a... Agent:

20120053170 - Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs: The present invention relates to nicotinamide derivatives of formula (I), to compositions containing same, and to the therapeutic use thereof, in particular as anticancer drugs. The invention also relates to the method for preparing said compounds, as well as to some of the intermediate products.... Agent: Sanofi

20120053171 - Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors: A compound represented by the formula [I]: or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a five-membered aromatic heterocyclic group or the like fused with a non-aromatic ring group, which may be substituted, Ring B represents a phenyl group or the like which may be substituted,... Agent:

20120053172 - Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders: The present invention relates to a method for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof, said method comprising administering to said mammal a pharmaceutically effective amount of a combination of a potassium channel activator and an anti-diabetic drug. The present invention... Agent: Cooperatieve Mirzorg U.a.

20120053173 - Heterocyclic compound: e

20120053174 - Quinazoline compounds and methods of use thereof: Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.... Agent:

20120053175 - Mlk inhibitors and methods of use: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition.... Agent: University Of Rochester

20120053178 - 3-(1,2,3-triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives: Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in claim (1), are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumours.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120053176 - Adenosine a3 receptor modulating compounds and methods of use thereof: Provided herein is a method of preventing, treating, or ameliorating one or more symptoms of an adenosine A3-mediated condition, disorder, or disease, with a compound of Formula I. Also provided herein is a method of preventing, treating, or ameliorating one or more symptoms of glaucoma or ocular hypertension. Further provided... Agent: Ambit Biosciences Corp.

20120053177 - Compounds and methods for kinase modulation, and indications therefor: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.... Agent: Plexxikon Inc.

20120053179 - Rho-kinase inhibitors: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.... Agent:

20120053180 - Cyclohexane analogues as gpr119 agonists: This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke,... Agent: Chemizon, A Division Of Optomagic Co., Ltd.

20120053181 - Pyrrolidine-derived beta 3 adrenergic receptor agonists: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.... Agent: Merck Sharp & Dohme, Corp.

20120053182 - Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease: The present invention provides a method for alleviating motor complications and motor indications in a patient suffering from moderate to severe Parkinson's disease by administering a composition which provides an effective amount of the compound of Formula I.... Agent: Schering Corporation

20120053183 - Piperazinylpyrimidine analogues as protein kinase inhibitors: The invention provides novel compounds based on piperazinylpyrimidine derivatives to be used as protein kinase inhibitors. The compounds may be useful in treating or preventing different cellular proliferation disorders, such as cancer. The present invention also provides methods of preparing these compounds, and methods of using the same.... Agent: University Of The Pacific

20120053184 - Salts of 3-(1h-ind0l-3-yl)-4-[2-(4-methyl-piperazin-i-yl)-quinazolin-4-yl]-pyrrole-2, 5-di one: The invention provides acid addition salts of 3-(1.H.-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-dione, crystalline forms thereof, processes for the preparation thereof, pharmaceutical compositions comprising them and uses thereof in therapeutic treatment.... Agent:

20120053185 - Method to treat melanoma in braf inhibitor-resistant subjects: Methods to treat cancer patients, especially melanoma patients, who have BRAF mutations and have become resistant to BRAF mutant kinase inhibitors employ inhibitors of multiple receptor tyrosine kinases. In addition, methods are described for identifying pharmaceutical compositions and drugs that will be successful in treating these patients.... Agent: Collabrx Inc.

20120053186 - 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors: Novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles of formula (I) that selectively modulate, regulate, and/or inhibit signal transductions mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective... Agent: Ab Science

20120053187 - Tri-cyclic pyrazolopyridine kinase inhibitors: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Incorporated

20120053188 - Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives: The invention encompasses a compound derived from hydroxamic acid that may be used to slow the expansion of cancer cells and thus is effective in the treatment of cancer. Generally, the disclosed compound includes a benzimidazole group coupled to a hydroxyamide of five or more unsubstituted carbon atoms and any... Agent: The Translational Genomics Research Institute(tgen

20120053189 - Btk inhibitors for the treatment of immune mediated conditions: Disclosed herein are pharmaceutical dosage forms of Brutons tyrosine kinase (Btk) inhibitors. Methods for the preparation of the compounds are disclosed. Methods of using the pharmaceutical dosage forms are disclosed for the treatment of immune mediated conditions and inflammatory diseases or conditions.... Agent: Pharmacyclics, Inc.

20120053190 - Organic compounds: The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.... Agent:

20120053191 - Oxidated derivatives of triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments: The present invention relates to new triazolyl purine derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders or cerebral ischaemia for which inhibition of adenosine A2A receptor will result at improving the health state of a patient.... Agent:

20120053195 - Hydrobromide salts of a pyrazolylaminoquinazoline: Provided herein are hydrobromide salts of a pyrazolylaminoquinazoline, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating a proliferative disease.... Agent: Ambit Biosciences Corp.

20120053193 - Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof: Provided herein is an optically active pyrazolylaminoquinazoline, and pharmaceutical compositions thereof. Also provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a JAK-mediated condition, disorder, or disease. Further provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a... Agent: Ambit Biosciences Corp.

20120053194 - Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof: Provided herein is an optically active pyrozolylaminoquinazaline, and pharmaceutical compositions thereof. Also provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a JAK-mediated condition, disorder, or disease. Further provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a... Agent: Ambit Biosciences Corp.

20120053192 - Heterocyclic substituted acardite derivate and application thereof: This present invention discloses a heterocyclic substituted acardite derivate and application thereof, namely compounds in the general formula (1) or the general formula (2) or pharmaceutically acceptable salts thereof, wherein A is monosubstituted or polysubstituted quinoline, isoquinoline, quinazoline, pyrrole or pyrimidine, and the substituent is halogen, C1-5alkyl, C1-5haloalkyl, C1-5alkoxy, C1-5haloalkoxy,... Agent: Jiangsu Provincial Institute Of Materia Medica Co. Ltd.

20120053196 - Combination treatment of breast cancer: The present disclosure provides products including an endocrine treatment product and a statin as a combined preparation for simultaneous, separate or sequential use in therapy. Further, there is provided a method of treatment of a mammalian breast cancer subject, comprising simultaneous, separate or sequential administration of therapeutically effective amounts of... Agent:

20120053197 - Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation: e

20120053199 - Noscapine and analogs and methods related thereto: The invention relates to the innate immune pathway and anti-inflammatory molecules with therapeutic properties. In some embodiments, the invention relates to compounds and pharmaceutical compositions and methods of using the compounds and compositions to treat inflammatory diseases including inflammation associated with auto-immune diseases.... Agent: Emory University

20120053198 - Water-soluble solid pharmaceutical inclusion complexes and their aqueous solutions for oral, ophthalmic, topical or parenteral use containing a macrolide and certain cyclodextrins: e

20120053200 - Bace 2 inhibitors:

20120053202 - Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof:

20120053201 - Substituted hydroxamic acids and uses thereof: wherein R1a, R1b, R1c, R1d, R2a, R2b, X1, X2, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or... Agent: Millennium Pharmaceuticals, Inc.

20120053203 - Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators: The invention relates to substituted 1-oxo-dihydroisoquinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.... Agent: Grunenthal Gmbh

20120053204 - Substituted quinoline-3-carboxamides as kcnq2/3 modulators: The invention relates to substituted quinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.... Agent: Grunenthal Gmbh

20120053206 - Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators: The invention relates to substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.... Agent: Grunenthal Gmbh

20120053205 - Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators: The invention relates to substituted 2-oxy-quinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.... Agent: Gr&#xfc Nenthal Gmbh

20120053207 - Antipsychotic treatment based on drd2 or ankk1 snp genotype: The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (SNP) associated with the dopamine receptor D2 (DRD2) and/or ankyrin repeat and kinase domain containing 1 (ANKK1) genes.... Agent: Vanda Pharmaceuticals, Inc.

20120053208 - Curcumin analogs as dual jak2/stat3 inhibitors and methods of making and using the same: Curcumin analogues and methods of making and using the same are disclosed.... Agent: The Ohio State University Research Foundation

20120053209 - Anticancer compounds, preparation thereof, and therapeutic use thereof: The invention relates to nicotinamide derivatives that can be used as anticancer drugs.... Agent: Sanofi

20120053210 - Compounds that modulate intracellular calcium: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel... Agent: Calcimedica, Inc.

20120053211 - Treatment of pancreatic cancer: The present invention relates to the field of oncology and relates to use of (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide or a pharmaceutically acceptable salt thereof or N-(4-(2-fluoro-4-iodophenylamino)-1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)cyclopropanesulfonamide or a polymorph thereof, or a pharmaceutically acceptable salt thereof, or pharmaceutical compositions comprising the same, for the preparation of a medicament for the treatment of pancreatic... Agent: Ardea Biosciences, Inc.

20120053212 - Methods of treating humans undergoing injection of a contrast agent: A human undergoing an injection of a contrast agent is treated by the administration of an iron chelator. Administration of the iron chelator can essentially prevent the onset of acute renal failure in a human. Administration of the iron chelator can reduce the severity of the acute renal failure and/or... Agent: Shiva Biomedical, LLC

20120053213 - 2-(4-substituted phenylamino) polysubstituted pyridine compounds as inhibitors of non-nucleoside hiv reverse transcriptase, preparation methods and uses thereof: The invention relates to 2-(4-Substituted phenylamino) polysubstituted pyridine compounds as inhibitors of non-nucleoside HIV reverse transcriptase, preparation methods and uses thereof. Specifically, the invention relates to compounds of formula I or the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in... Agent: Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.l.a. China

20120053214 - The little molecule compound which used for promoting the stem cells hyperplasia and the use thereof: The invention provides small molecule compounds capable of accelerating proliferation of stem cells and uses thereof. The compounds play an important role in the research of stem cell proliferation mechanism. The invention further relates to the uses of the compounds and relevant compounds thereof in the preparation of stem cell... Agent:

20120053215 - Isothiazolone-containing preservative with improved effectiveness: A preservative which comprises a) one or more isothiazolones and b) one or more glycerol monoalkyl ethers, and the use of the preservative for microbicidal finishing of cosmetic and pharmaceutical products.... Agent: Air Liquide Sante (international)

20120053217 - Composition for preparing emulsion or microemulsion formulations: Provided is a composition for preparing emulsion or microemulsion formulations that demonstrates favorable dilution properties without being affected by the solubilities of constituent components. The composition for preparing emulsion or microemulsion formulations contains a component (A): a polyoxyalkylene allyl phenyl ether, polyoxyalkylene aralkyl phenyl ether or polyoxyalkylene aralkenyl phenyl ether,... Agent: Nippon Soda, Co., Ltd

20120053216 - Pesticidal compositions: o

20120053218 - Triazole derivatives as vasopressin-receptor inhibitors for treating cardiac insufficiency: The present application relates to novel substituted phenylalanine derivatives, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment... Agent: Bayer Pharma Aktiengesellschaft

20120053219 - Processes of making and using pharmaceutical formulations of antineoplastic agents: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent... Agent: Schering Corporation

20120053220 - Novel lipoxygenase inhibitors as neuroprotective agents: The present invention relates to the identification of inhibitors of lipoxygenase enzymes. Methods are presented for using novel lipoxygenase inhibitors: LOXBlock-1 and LOXBlock-3, and other candidate lipoxygenase inhibitors identified by similar screening strategies, in therapy and diagnostics for neurodegenerative disorders.... Agent: The Regents Of The University Of California

20120053221 - Polymers for increasing the soil mobility of low-solubility insecticides: What is described is use of a polymeric solubilizer for increasing the soil mobility of a sparingly soluble insecticide, said polymeric solubilizer having the property that the active insecticidal ingredient in a 1% by weight aqueous solution of the polymeric solubilizer at 25° C. and 1.01325 bar has a solubility... Agent: Basf Se

20120053222 - Novel metabolic disease therapy: The invention relates to the prevention and treatment of metabolic abnormalities characterized by abnormal glucose metabolism, including diabetes mellitus and new onset diabetes mellitus through the use of fibroblast activation protein (FAP) selective inhibitors.... Agent:

20120053235 - Dihydromyricetin as an ikk-beta inhibitor used for treatment of arthritis, cancer and autoimmune conditions, and other diseases or disorders: Use of dihydromyricetin (DMY) as an NF-κB inhibitor or an IKK-β inhibitor for the treatment of arthritis, cancer, autoimmune conditions and other disease is provided. A pharmaceutical composition comprising DMY is also provided.... Agent: Hong Kong Baptist University

20120053236 - Pharmaceutical composition for diabetic nephropathy and its preparation and application: The invention relates to application of 4,4′-diphenylmethane-bis(methyl) carbamates (DPMC) extracted and isolated from Cortex Mori and preparation of medicine for diabetic nephropathy. The pharmaceutical composition is made up of DPMC as active ingredient and the normal drug carriers, and the weight percentage of active ingredient is 0.1-99.5%. For the remarkable... Agent: Guangzhou Consun Medicine R & D Co., Ltd.

20120053237 - Oligomer-amino acid conjugates: The invention relates to (among other things) oligomer-amino acid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated amino acid compounds.... Agent: Nektar Therapeutics

20120053238 - Solid retigabine in non-crystalline form: The invention relates to solid retigabine in non-crystalline form together with a surface stabiliser in the form of a stable intermediate. In the intermediate of the invention, retigabine is preferably present in amorphous form or in the form of a solid solution. The invention further relates to processes for the... Agent: Ratiopharm Gmbh

20120053239 - Treatment for intestinal gas, bloating, microscopic colitis, inflammatory bowel disease and traveler's diarrhea using colloidal bismuth subcitrate: A method of treatment for intestinal gas bloating, microscopic colitis, traveler's diarrhea and inflammatory bowel disease, said method comprising ingesting an effective quantity of a composition comprising colloidal bismuth subcitrate to eliminate gastrointestinal discomfort.... Agent:

20120053240 - Method of administering beta-hydroxy-beta-methylbutyrate (hmb): A method of administering beta-hydroxy-beta-methylbutyric acid (HMB) is described, and specifically administering HMB-acid to a person such that the administration of free acid HMB results in an increase in effectiveness of HMB over administration of other forms of HMB, including a calcium salt HMB composition is described. Administration of HMB-acid... Agent: Metabolic Technologies, Inc.

20120053241 - Aqueous nanoemulsion composition containing conjugated linoleic acid: The present invention relates to an aqueous nanoemulsion composition comprising conjugated linoleic acid. More particularly, the present invention relates to an aqueous nanoemulsion composition comprising 5 to 50 wt % of conjugated linoleic acid, 0.01 to 5 wt % of lecithin, 0.01 to 5 wt % of ethanol as a... Agent: Hwail Pharmaceutical Co., Ltd.

20120053242 - Compositions rich in omega-3 fatty acids with a low content in phytanic acid: The current invention refers to the procedure to obtain compositions rich in omega 3 fatty acids with content in phytanic acid below 90 μg per gram of oil. The current invention also refers to the obtaining of compositions rich in DHA with a content in phytanic acid below 90 μg... Agent: Cela Vista Pharmaceuticals Limited

20120053243 - Parakeratosis inhibitor and skin preparation for external use: To provide a parakeratosis inhibitor, pore reducing agent and skin roughness preventing/ameliorating agent that exhibit capabilities of parakeratosis inhibition, pore reduction, skin roughness prevention/amelioration, etc., and further provide a skin preparation for external use having these capabilities. There are provide a parakeratosis inhibitor and a pore reducing agent each comprising... Agent: Shiseido Company, Ltd.

20120053244 - Alkylamido compounds and uses thereof: Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.... Agent:

20120053245 - Methods of treating hair related conditions: Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.... Agent:

20120053246 - Purification process for preparing highly pure arformoterol tartrate substantially free of desformyl impurity: Provided herein is a highly pure arformoterol tartrate or an amorphous form thereof substantially free of desformyl impurity, 2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]aniline, process for the preparation thereof, and pharmaceutical compositions comprising the highly pure arformoterol tartrate substantially free of the desformyl impurity.... Agent: Actavis Group Ptc Ehf

20120053247 - Method of improving cardiovascular health: A nutritional supplement including β-cryptoxanthin is found to be effective at lowering blood pressure in mammals. β-cryptoxanthin therefore may be used to maintain cardiovascular health by lowering blood pressure, preventing high, elevated blood pressure and/or maintaining healthy blood pressure. Administration of β-cryptoxanthin in combination with safflower oil is particularly effective.... Agent:

20120053248 - Solid pharmaceutical preparations containing copolymers based on polyethers combined with poorly water-soluble polymers: The invention relates to dosage forms which contain preparations of poorly water-soluble substances in a polymer matrix of polyether copolymers, said polyether copolymers being obtained by the radically initiated polymerization of a mixture from 30 to 80% by weight of N-vinyl lactam, 10 to 50% by weight of vinyl acetate... Agent: Basf Se

20120053249 - Compressible and free-flow co-agglomerates of mannitol and granular starch: Co-agglomerates of crystalline mannitol and granular starch, characterised in that they have a compressibility, as determined according to a test A, higher than 120 N, and preferably of 200 to 450 N, and a flow time, as determined according to a test B, of 3 to 15 seconds, and preferably... Agent: Roquette Freres

20120053250 - Polymer shells: The present invention relates to a method for the preparation of polymer shells, preferably composed of cellulose or hemicellulose, comprising the steps of dissolving the polymer component in a first solvent, preferably an organic solvent and precipitating the polymer component by contacting the first solution with a second solvent, which... Agent: Swetree Technologies Ab

20120053251 - Fat emulsion providing improved health and taste characteristics in food: The embodiments relate to fat emulsion structures based on both an aqueous and non-aqueous glycerin component as the primary aqueous component in which the fat emulsion can create a wide range of viscosities that mimic fat structures similar to cream, or all the way to hardened fat structures like Trans... Agent: Antioxidant Superfoods, Inc.

20120053252 - Fluorinated ethoxylated polyurethanes: The present invention comprises fluorinated ethoxylated polyurethanes of formula [Rf—(X)n—(CH2CHR1—O)m—CH2CH2—O—C(O)—NH]p-A, wherein Rf is a C1 to C6 perfluoroalkyl; X is a divalent radical; n is 0 or 1; R1 is H or C1 to C4 alkyl; m is 1 to 20; p is a positive integer of at least 2;... Agent: E.i. Du Pont De Nemours And Company

20120053253 - Gene signatures for cancer prognosis: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.... Agent: Myriad Genetics, Incorporated

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140710: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 4.27704 seconds

PATENT INFO